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Burkholderia cepacia complex (Bcc) species are opportunistic pathogens in pa-
tients with cystic fibrosis (CF), which are able to cause lethal infections. The
Bcc are inherently resistant to most classes of antibiotics, which makes success-
ful treatment problematic. Lipid A (also known as endotoxin), the hydrophobic
anchor of lipopolysaccaride (LPS), is the bio-active component of LPS. One of
several unique characteristics of the lipid A of the Bcc, is the permanent attach-
ment of 4-amino-4-deoxy-L-arabinose (L-Ara4N) to the lipid A molecule. Also,
the genes involved in L-Ara4N biosynthesis are necessary for viability in B. ceno-
cepacia. Here we present research on lipid A biosynthesis, modification, and
transport in the Bcc and highlight promising antimicrobial targets.
The synthetic antibiotic CHIR-090 is an inhibitor of LpxC, an enzyme involved
in the lipid A biosynthetic pathway. I investigated the activity of CHIR-090
against the Bcc and found that sensitivity to this antibiotic was both species- and
strain-specific. CHIR-090 displayed MICs between 0.1 and 12.5 µg/ml against
a panel of B. multivorans, the most prevalent Burkholderia species in CF. The
species- and strain-specific sensitivity towards CHIR-090 was further explored
and a strong correlation was found between the presence of a unique open read-
ing frame, named LpxC2, in resistant species.
To address the problem of multiple drug-resistance of the Bcc, we investigated
the activity of the pyridoxal 5′-phosphate (PLP)-dependent enzyme inhibitor cy-
closerine (CS) against the Bcc. CS is used as a second line of defense against
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M. tuberculosis. The activity of the D-enantiomer of CS (DCS) against the Bcc
was tested and displayed MICs between 2 and 128 µg/ml and acted bacterici-
dal towards the Bcc. Additionally, DCS inhibition of recombinant ArnB from
B. cenocepacia J2315, a PLP-dependent enzyme necessary for viability in the
Bcc, was studied. ArnB was inhibited reversibly by DCS. ArnB was further ex-
plored as a promising drug-target in the Bcc, but only CS has been identified as
an inhibitor so far.
In this thesis it was attempted to find the reason why is L-Ara4N modifica-
tion of lipid A necessary for viability in B. cenocepacia. Therefore, two proteins
were characterised, which are involved in lipid A transport: LptA, the periplas-
mic lipid A binding protein, and LptB, the cytoplasmic ATP-ase. LptA was
found to be able to bind both modified and unmodified lipid A in vitro and
therefore is not L-Ara4N specific. Furthermore, LptA could bind deep-rough-,
rough-, and smooth- LPS, similar to that described for Escherichia coli LptA.
The kinetic parameters of LptB were determined in vitro (kcat = 5.71 min
−1 and
KM = 0.88 mM), and were comparable to E. coli LptB. The ATP-ase activity
of LptB was not influenced by the presence of any forms of LPS (modified or
non-modified). Therefore, we concluded that both B. cenocepacia J2315 LptA
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1.1 Cystic fibrosis and microbiology
Since medieval times an association between young children with a salty skin and
early death has been observed. We now know these children were most likely
suffering from the most common (1 in 2,500) inherited condition in Caucasians,
cystic fibrosis (CF).
Wehe dem Kind, das beim Kuss auf die Stirn salzig schmeckt,
es ist verhext und muss bald sterben. Alemannic proverb from
the 17th century
(Woe is the child that tastes salty when kissed on the forehead, it is be-
witched and must die soon.)
CF was firstly recognized as a disease in 1938 by Dr. Dorothy H. Anderson, who
linked pancreatic changes with steatorrhoea (increased fat in the faeces) and pneu-
monia (inflammation of the lung tissue), and hypothesized that the CF condition
was the result of a recessive genetic defect [1]. In the fifties, Paul di Dant’Agnese
and coworkers found proof for increased concentrations (≥ 60 mEq/L) of sodium
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and chloride in the sweat of CF patients [2, 3], a feature that could be used to ac-
curately diagnose this condition. The CF diagnosis test, suggested by Shwachman
et al., was performed by placing a patient’s body in a plastic bag for 30 minutes
to over 2 hours to arouse sweating [4]. Gibson and Cooke recognized the obvi-
ous risks associated with this procedure, which they could replace by a simpler
and safer test, in which pilocarpine is introduced into the skin by iontrophoresis,
thereby stimulating localized sweating [5].
At the end of the 1990s the ’CF gene’ was identified on the long arm of chromo-
some 7. This 250 kB gene, encoding a predicted protein of 1,480 amino acids of,
at that time, unknown function. Sequence analysis revealed that it consists of two
similar motifs, both having a membrane association and an adenosine triphos-
phate (ATP) domain (an ABC transporter homologue). In 1989, the research
groups of Francis Collins, Lap-Chee Tsui and John Riordan, simultaneously pub-
lished a description of ”the identification of the CF gene” in the same issue of
Science [6, 7, 8]. Knowing which gene is responsible for CF made a more refined
diagnosis of the disease possible. Additionally, the ability to detect mutations
in the ’CF gene’ at the DNA level showed that around 70% of the CF patients
have a specific deletion of 3 base pairs in the gene, encoding a phenylalanine
residue. This was described as mutation ”∆508.” The remaining 30% of patients
have different and often multiple mutations in the gene [6], and today over 1,600
mutations have been reported [9].
The observation that CF patients seem to have a chloride permeability defect sug-
gested that the ’CF gene’ either encodes for a Cl− channel itself or encodes a Cl−
channel regulator. Hence, the protein was named ”cystic fibrosis transmembrane
conductance regulator” (CFTR). In 1992, three years after the discovery of the
CF gene, John Riordan and co-workers published the purification of recombinant
CFTR and showed that upon incorporation of the protein into proteoliposomes,
regulated Cl− channel activity could be detected [10]. At present, it is known
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that CFTR is an ATP-driven ion channel that transports Cl− across the plasma
membrane and is needed for optimal water flow in epithelial cells. Malfunction
or absence of CFTR leads to dehydrated mucus accumulation in all organs con-
taining exocrine epithelia, such as the lungs, intestines, pancreatic ducts, testes
ducts, and sweat gland ducts [11, 12].
A striking characteristic of CF is the higher susceptibility to bacterial infections of
the respiratory tract [12, 13]. This is due either to the accumulation of dehydrated
mucous that obstructs the cilia and other pulmonary clearance mechanisms, or
to the absence of the hypotonic salt gradient caused by lowered Cl− transport
over the membrane [14]. In either case, without intensive antibiotic therapy to
delay or treat early lung infections, chronic microbial infection of the lungs leads
to acute exacerbations and pulmonary failure, the principal causes of morbidity
and mortality in individuals with CF.
In wine there is truth, in beer there is strength, in water
there is bacteria German proverb
Historically, the major pathogens recovered from the sputum of CF patients were
considered to be Staphylococcus aureus, Haemophilus influenza and Pseudomonas
aeruginosa. However, recently the role of anaerobes and other potential pathogens
has been questioned [15]. In the last two decades, species of the Burkholderia
cepacia complex (Bcc), have increasingly been isolated from the CF lung [12, 16,
17] and since 2002, a rising number of Burkholderia pseudomallei infections have
been reported [18, 19, 20, 21, 22, 23]. B. pseudomallei is well known as the highly
virulent agent of melioidosis, a life-threatening disease endemic in southeast Asia
and northern Australia [24].
Though the risk of Bcc infection is relatively low in healthy humans, it is of
great concern for CF patients. In most organ transplant centres, isolation of
Bcc is a contraindication for life-saving surgery. Furthermore, infection by Bcc
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leads, in approximately one third of infected individuals, to a septic shock, the
so-called ’Cepacia syndrome.’ This life-threatening syndrome is characterised
by necrotizing pneumonia which culminates in a rapid decline of lung function
and can ultimately lead to the death of the patient [25]. Furthermore, Bcc in-
fections are transmissible from one patient to another [12], leading to epidemic
outbreaks [26, 27], and cannot be treated due to the resistance of Bcc to most an-
tibiotics. Taking all of this into account, it is widely accepted that Bcc infection
requires the segregation of infected individuals from the rest of the CF popula-
tion, a draconian form of infection control which has a major impact on both the
psychological well-being of the patient and the (re-) organization of clinics [28].
Though quality of life and life expectancy has greatly increased for CF patients
in the 20th century (from a short and painful life to an average life time of 30-40
years), due to the wide use of antibiotics and refinement of conventional care [29],
the management of lung infections remains challenging. In particular, treatment
of Bcc infections is severely limited by the innate broad-spectrum resistance of
these bacteria. As evidence, only four cases of successful antibiotic treatment of
Cepacia syndrome have been reported, and in all cases required a combination
of at least four antibiotics [30]. Clearly, there is an obvious and urgent need for
new antimicrobial agents that are effective against Bcc infections.
Although CF clinics have been confronted with Bcc for over two decades, includ-
ing several major intercontinental epidemic outbreaks, it is still not understood
why Bcc, in contrast to other species, can trigger such a rapid pulmonary de-
terioration. Further research is needed on virulence factors of Bcc and on the
differences in these factors when compared to other CF pathogens. This research
is fundamental to gain knowledge and discover Bcc’s Achille’s heel that could be
targeted by new antimicrobial agents.
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1.2 Burkholderia cepacia complex and virulence
factors
The Bcc comprises an expanding group of closely-related Gram-negative bacteria
with a complex taxonomy. Initially recognized by Walter Burkholder as the
causative agent of onion rot, and originally known as Pseudomonas cepacia [31],
these organisms were first recovered from the CF lung in the late 1970’s. In 1992,
several Pseudomonas species, including P. cepacia, were reclassified (based on
rRNA sequences) to the new genus Burkholderia and P. cepacia was renamed
Burkholderia cepacia [32]. Around the same period, recognition of the genomic
diversity in B. cepacia isolates from CF patients led to the introduction of the
term Bcc to describe organisms comprising of at least five different species [33,
34, 35, 36]. At present, the Bcc consists of 17 species (Table 1.1) the majority of
which have been recovered from CF patients [37]. As an aid to Bcc studies, two
panels of Bcc reference isolates have been assembled representing the first nine
species recognised [35, 38]; these include both environmental and clinical isolated
strains.
Table 1.1: The Burkholderia cepacia complex (Bcc)
genomovar species name genomovar species name
I B. cepacia X B. ubonensis
II B. multivorans XI B. latens
III B. cenocepacia XII B. diffusa
IV B. stabilis XIII B. arboris
V B. vietnamiensis XIV B. seminalis
VI B. dolosa XV B. metallica
VII B. ambifaria XVI B. contaminans
VIII B. anthina XVII B. lata
IX B. pyrrocinia
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Bcc are non-spore forming bacteria that are naturally found in water, soil, and
are particularly associated with the rhizosphere of plants [39]. In addition to
their non-phytopathogenic role, Bcc can cause opportunistic infections in CF
patients and life-threatening pneumonia in patients with chronic granulomatous
disease. Therefore, the Bcc is one of the rare examples of a pathogen that is
shared by both plants and humans [40]. It has been shown by several research
groups that Bcc, like some other bacterial species, can enter mammalian cells,
survive, and depending on the cell-line used, replicate intracellularly [41, 42, 43].
Bcc species can survive in activated macrophages and respiratory epithelial cells,
features that might add to their pathogenicity in CF patients [44, 45]. Some Bcc
strains produce a brown melanin-like pigment (studies on B. cenocepacia suggest
a pyomelanin), that can protect the cells from intracellular oxidative stress [46].
Species of the Bcc are extremely metabolically versatile [47, 48], capable of de-
grading a wide variety of compounds, including some man-made pollutants (such
as trichloroethylene and polychlorinated biphenyls) [49]. This is exemplified in the
case of B. multivorans as its name means ”the eater of everything.” In addition,
Bcc are capable of long-term survival under minimal nutritional conditions [12].
They are found in pharmaceutical solutions, shampoo, hospital equipment, ”ster-
ile solutions” [35, 50], and are the main contaminant in water supplies of space
shuttles [51]. At the end of 2009, Bcc made it into the UK news, by contaminat-
ing Vicks Sinex nasal spray (Proctor & Gamble), leading to the recall of 120,000
bottles. As mentioned above, the main difficulty with handling Bcc is that they
are extra-ordinarily resistant to antimicrobial agents. This is exemplified by their
ability to use penicillin G as a sole carbon source [52].
Ironically, in contrast to their pathogenic and contaminating role, members of
the Bcc can be highly beneficial in the natural environment. Some species are
able to fix nitrogen within the rhizospheres of crops and thereby promote plant
growth. Due to their metabolic versatility Bcc has considerable potential for
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bioremediation purposes [16]. They can produce anti-fungal compounds (cepacin,
altercidins, cepacidines, siderophores, and pyrrolnitrin) that prevent molding of
fruit and root rot of seedlings (ironically, anti-fungal compounds excreted by
Bcc may inhibit colonization of Candida and other fungal species in the CF
lung) [12, 16, 53].
Several studies have focused on the capability of Bcc strains to compete with
other bacterial species. Forty percent of Bcc species show antibiotic activity
against other Bcc species and other Gram-negative bacteria. B. ambifaria shows
the greatest antimicrobial potential among the Bcc strains tested. One of the
interesting antimicrobial compounds, recently isolated from B. ambifaria, has
been identified as the known natural product enacyloxin [54]. Future research
might lead to the identification of other novel compounds produced by Bcc strains
that can be used to treat infections.
The biotechnological potential of the Bcc as biopesticides and bioremediation
agents to reduce global pollution stands in contrast to their pathogenicity and has
led to an intense debate between agricultural- and medical microbiologists [17,
55, 56]. On the one hand, the agricultural microbiologists argue that not all
Bcc strains might be pathogenic for humans and thus could be released in the
environment [17]. On the other hand, medical microbiologists argue that Bcc
infections are likely to be directly acquired from the environment [57] and that
there is not enough evidence for lack of virulence of any of the species [55, 56].
As a result of this ongoing debate, the U.S. Environmental Protection Agency
presently restricts the use of Bcc species for biotechnological applications.
Bacterial systematics and the Bcc
In bacterial systematics, typically the 16s rRNA gene sequences are used to iden-
tify new species or distinguish between them. However, between the different
Bcc strains there is limited sequence variation (98-100% identity) in this gene. In
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contrast, the recA gene (encoding a protein essential for repair and recombination
of DNA) shows sufficient variation between Bcc species and can be used for iden-
tification. The recA gene is first amplified, using Bcc specific primers, followed
by a restriction fragment length polymorphism (RFLP) analysis [38]. Different
species can be distinguished based on their RFLP profile. This method has been
proven to be accurate to identify species directly from sputum of CF patients and
after selective culturing [38, 58]. As yet, RFLP profiles have not been published
for all Bcc species.
1.2.1 Clinical relevance & epidemic strains
In the absence of epidemic outbreaks, Bcc is recovered from 5-10% of the adult
CF population and, in 80% of the Bcc infections, the isolates are identified as
B. cenocepacia or B. multivorans [16, 59]. These infections are either obtained
from patient-to-patient transmission or acquired from the environment with some
geographical variation in prevalence of the different Bcc species. After infection,
the clinical outcomes differ greatly from patient to patient even when the same
strain is involved. In some patients there is little increase in morbidity, whereas
other patients have a rapid decline of lung function and die soon after infection.
Before the introduction of strict patient segregation, some Bcc isolates were trans-
mitted readily from one CF patient to another, resulting in serious epidemic out-
breaks [26, 27]. B. cenocepacia is the most virulent species and accounts for most
epidemics in the CF population. However, B. multivorans was responsible for a
dramatic epidemic outbreak in 1992 amongst CF children in Glasgow [60]. The
most prevalent epidemic B. cenocepacia strains in the UK [26] and Canada [61]
belong to the particularly virulent, clonal, ET-12 lineage [62] and are highly trans-
missible. The main strains used in this thesis are B. cenocepacia strain J2315,
responsible for an epidemic outbreak in Edinburgh in 1989 [26], and B. ceno-
cepacia strain K56-2 [63], clinically isolated in Canada, both are members of the
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ET-12 lineage.
B. cenocepacia consists of four different subgroups based on recA sequencing and
RFLP analysis: IIIA, IIIB, IIIC, and IIID [64]. The clinical significance of the
different subgroups is unclear but all the members of the ET-12 lineage belong to
subgroup IIIA. The genome of B. cenocepacia J2315 and nine other Bcc strains
have been sequenced and are available on www.burkholderia.com. J2315 has a
total genome size of 8,056 Mb and a 66.9% GC content. The genome is divided
into three large chromosomes and a small 92-kb plasmid. The inherent resistance
of members of the Bcc has been linked to the relatively large ( 8-9 Mbp) genomes
of these bacteria which contain multiple antibiotic resistance genes [65].
1.2.2 Virulence factors
Most Bcc species produce a wide variety of putative virulence factors that might
cause Cepacia syndrome, but none of these factors has been established as the
main causative agent. Bcc can produce proteases, siderophores, hemolysin, cy-
totoxins, catalases [12] and an exopolysaccharide (EPS), called Cepacian. Cepa-
cian is capable of interfering with antimicrobial peptides (AMPs) and therefore
inhibits peptide-based immune defenses [66]. Production of Cepacian is induced
by growth on certain carbohydrates, in particular mannitol [67].
Members of the ET-12 lineage have shown to have cable pili and possess the epi-
demic strain marker (bcesm). Cable pili are able to bind to the cytokeratin 13
receptor that is overexpressed in CF lung epithelial cells and therefore is likely to
induce cytokine production. Bcesm is a DNA fragment, found in some epidemic
strains but not in non-epidemic CF strains, that contains a number of virulence
determinants [68, 69]. Furthermore, Bcc have shown the ability to form biofilms
in vitro, with both P. aeruginosa and other Bcc. This feature may increase resis-
tance to antibiotics and host-defense mediators. However, it has been reported
recently that in vitro biofilm formation of Bcc has no effect on the susceptibility
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to the six most commonly used antibiotics [70].
Like for many other Gram-negative bacteria, lipopolysaccharide (LPS), the main
component of the outer membrane, is a virulence factor in Bcc. LPS, also referred
to as endotoxin, is a bioactive molecule that can activate the immune system by
forming a Toll-like receptor (TLR4)-MD2-LPS complex (the structure of this
complex has been solved recently [71]), thereby inducing pro-inflammatory cy-
tokines [72]. Before 1997 and the expansion of Bcc taxonomy, LPS from ’B. cepa-
cia’ was shown to be highly pro-inflammatory, and elicited a nine-fold higher
release of tumor necrosis factor alpha (TNF-α) from monocytes compared to the
LPS from P. aeruginosa [73]. In the same ”pre-Bcc period,” the interaction of
’B. cepacia,’ E. coli and P. aeruginosa LPS with neutrophils was investigated.
It was shown that both E. coli and ’B. cepacia’ LPS increased CD11b (involved
in phagocytosis) and complement receptor 3 (CR3, involved in transmigration)
expression on neutrophils. Moreover, their LPSs are potent priming agents for a
respiratory burst response. However, P. aeruginosa LPS had little to no effect on
CD11b and CR3 expression and primed neutrophils to a low degree [74]. TNF-α
production by human monocytes, stimulated by ’B. cepacia’ LPS, was four-fold
greater than for P. aeruginosa LPS. Levels of monocyte cytokine production,
stimulated by whole ’B. cepacia’ cells were found to be similar to extracted LPS,
suggesting that this virulence factor plays a prominent role in inflammation [75].
Subsequently, the proinflammatory activity of the first five Bcc species was com-
pared. It was shown that there is a difference in TNF-α induction between species
and strains within the same species. Interestingly, amongst the Bcc, B. cenocepa-
cia isolates cause the greatest cytokine induction [76].
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1.3 Lipopolysaccharides
In 1676, the Dutch scientist Antonie van Leeuwenhoek first discovered the ”ex-
istence of bacteria” by using a single-lens microscope that he designed himself.
About 200 years later, in 1884, Christian Gram developed a staining method to
visualize bacteria, that turned out to be capable of distinguishing between Gram-
positive and Gram-negative bacteria. However, it was not until the development
of the electron microscope that the distinctive cell envelope of Gram-negative
bacteria was discovered [77].
There is no doubt that the discovery of regular arrays of
morphological units in the surface layers of some bacteria is
one of the exciting achievements of electron microscopy and
raises many interesting questions, both in microbiology and
in the wider fields of cell and molecular biology. Glauert &
Thornley 1969
The cell envelope of Gram-positive bacteria consists of two layers, the cytoplas-
mic or inner membrane (IM), surrounded by a thick peptidoglycan layer. The
cell envelope of Gram-negative bacteria (Figure 1.1) on the contrary consists
of three layers, the IM, a thinner peptidoglycan layer, and the outer membrane
(OM). The IM consists of a phospholipid bilayer and proteins. The peptidoglycan
layer or periplasm, mainly consists of peptidoglycan, teichoic acids and soluble
proteins. The OM encapsulates the peptidoglycan and is composed of an asym-
metrical bi-layer and proteins. The inner leaflet of the bi-layer is formed from
phospholipids and the outer leaflet primarily from LPS [78]. LPS is stabilized by
associated cations (e.g. Mg2+) which form salt bridges between the electrostati-
cally repulsive LPS molecules. LPS on the outer surface of bacteria improves the
barrier function, making Gram-negative bacteria resistant to antibiotics that can
be successfully used to treat Gram-positive infections [79].
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Figure 1.1: Schematic representation of the cell envelop of Gram-negative bacte-
ria. Adapted from [80].
LPS consists of three structural domains, the conserved lipid A domain, the
polysaccharide core, which can be divided into the inner core and the outer core,
and the highly variable extended polysaccharide region, called the O-antigen [81]
(Figure 1.2). All three domains are not consistently present. Strains containing
all three domains, are referred to as ”smooth”. If the envelope lacks the O-
antigen region, it is called ”rough”. If it lacks the O-antigen and outer core, it
is called ”deep-rough.” Deep-rough LPS seems to be the minimal requirement
for viability in most Gram-negative bacteria [82] in their natural environment.
However, strains have been modified, so that only the lipid A domain is expressed,
and they are viable when grown under laboratory conditions [83]. Lipid A is the
hydrophobic anchor moiety of LPS that builds the outer monolayer of the OM
and is the bioactive component of LPS that can activate the immune system. For
Bcc species it has been shown that the level of cytokine induction is the same
for both smooth- and rough- LPS-containing strains [76]. For the purpose of this
thesis, only the lipid A and inner core domains are discussed.
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Figure 1.2: Schematic representation of the three structural domains of LPS.
Adapted from [80].
1.3.1 Lipid A and inner core structures
The lipid A backbone is relatively conserved among Gram-negative bacteria. It
consists of a typical β(1′ -6)-linked disaccharide of glucosamine, which is tetra-,
penta-, or hexa- acylated. The glucosamine is glycosylated in most species with
one, two, or three 3-deoxy-D-manno-octulosonic acid (Kdo) sugars at position 6′,
as shown in Figure 1.3.
Studies of LPS not only showed us the impressive diversity
of LPS structures in the bacterial kingdom but also led to
the realization that the LPS structure may be modified in re-
sponse to the conditions prevailing the environment. Hiroshi
Nikaido, 2003 [79]
Lipid A is considered as the most conserved component of LPS, but the diversity
in structure is still broad. The lipid A of every bacterial species (or genus) iden-
tified so far seems to be unique in the length and number of incorporated fatty
acids and the presence or absence of certain lipid A modifications (Figure 1.3).
Lipid A modifications may help Gram-negative bacteria to adapt and resist envi-
ronmental stress and are mediated by changes in the local environment, such as
changes in calcium-concentration, pH, temperature, and the presence of AMPs.




Figure 1.3: A) Kdo2-lipid A of E. coli. B) Common lipid A modifications of
Gram-negative bacteria. Pink= incorporation of phosphoethanolamine; blue=
incorporation of L-Ara4N; green= addition or removal of fatty acids; orange=
addition of a phosphate group; brown =addition of a hydroxyl group on a fatty
acid; red= addition of hydroxyl group in one of the Kdo residues. Adapted from
[81, 84, 85].
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AMPs, and can change the immuno-stimulation potential of lipid A [86, 84, 87].
Unsaturated fatty acids can be incorporated when the bacteria are grown at lower
temperatures to adjust the OM fluidity [88].
The attachment of 4-amino-4-deoxy-L-arabinose (L-Ara4N) and/ or phospho-
ethanolamine, at the phosphate groups at 1 and 4′, or to the outer Kdo residue
are common modification strategies of Gram-negative species. Such modifications
lead to resistance to polycationic compounds, such as polymyxin B (PmxB) [81,
89, 90], that enter the cell via a self-promoted uptake mechanism, by binding to
LPS. When PmxB binds to LPS it displaces Mg2+, thereby disrupting the Mg2+
cross bridges between anionic LPS molecules and destabilizing the OM [91, 92]. L-
Ara4N reduces the net negative charge of lipid A, resulting in a reduced binding
affinity of PmxB [79]. Instead of L-Ara4N, various species incorporate galac-
tosamine or galacturonic acid residues in the lipid A.
In addition, some lipid A structures lack the phosphate group at the 1 or 4′
position, or have a diphosphate at those positions. In a few species, the hydrogen
group on the anomeric carbon atom at position 1 is oxidized to a lactone after
removal of the phosphate group [87]. In a small number of species, including
Burkholderia species, an additional hydroxyl group is incorporated at C3 of one
of the Kdo residues to form D-glycero-D-talo-oct-2-ulopyranosylic acid (Ko) in
the inner core. Most enzymes involved in the lipid A modifications, found up to
now, have been identified [87].
Lipid A structure of the Bcc
Bcc are highly resistant to the majority of antibiotics, including PmxB. This re-
sistance, together with the fact that no detectable amounts of Kdo sugars could
be found in the cell digest of ’B. cepacia,’ suggested that this bacterium has
a unique lipid A structure. In 1991, Cox and Wilkinson were the first to re-
port that the lipid A of ’B. cepacia’ contains a single Kdo sugar. They con-
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cluded that PmxB resistance is most likely the consequence of the low number
of carboxylate and phosphate groups as well as the presence of L-Ara4N [93].
Later in 1998, a characteristic Ko-Kdo disaccharide in the inner core region of
B. cepacia ATCC 25416 was identified. The Ko residue of the disaccharide was
non-stoichiometrically substituted with L-Ara4N at position 8 [94]. The lipid A
structure of B. cepacia ATCC 25416 was further characterised and showed to
have a bisphosphorylated glucosamine backbone with L-Ara4N residues attached
on both phosphates [95]. More recently, lipid A structures, with or without inner
core, have been described for a number of Bcc species, including B. cenocepa-
cia J2315 [96], B. cepacia BTS7 [97], B. cepacia ATCC 25416, B. multivorans,
B. vietnamiensis, and B. pyrrocinia [28]. The different structures show many
common features (Figure 1.4).
Figure 1.4: Lipid A structure found in Bcc species, showing the lipid A backbone
(black), non-stoichiometrical substitution of L-Ara4N (blue), the OH group of
the Ko residue (red), and the diversity in number of fatty acids (green). Adapted
from [28].
The lipid A contains a β(1′-6)-linked disaccharide of glucosamine that is phospho-
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rylated at the 1- and 4′- positions, derivatized C16:0 (3-OH) and C14:0 (3-OH)
as primary fatty acids and C14:0 as a secondary fatty acid. The inner core struc-
tures all contain a Ko-Kdo disaccharide, in which L-Ara4N can be attached to
the Ko residue. L-Ara4N can also be attached to both phosphate groups. Hence,
the lipid A of Bcc has the potential to be biosynthesized with three L-Ara4N
residues. Recently, the Campopiano group, in collaboration with researchers at
the Centre of Infectious diseases (Edinburgh University) and the Infectious Dis-
eases Research Group of the University of Western Ontario, showed that the
putative genes involved in L-Ara4N biosynthesis (discussed in section 1.5) are,
unlike in other Gram-negative bacteria, necessary for viability in B. cenocepa-
cia [98]. This finding, together with the available lipid A structures, suggests
that L-Ara4N is always present in Bcc LPS.
To date, isolated lipid A species have been shown to be penta- or tetra-acylated:
hexa-acylated structures have not been identified in Bcc. It is interesting to note
that from research on lipid A from other species, the general consensus is that
lipid A molecules with less than six fatty acids are less immuno-stimulatory, and
might even act as an LPS antagonist. However, Bcc lipid A always contains fewer
fatty acids and is still capable of inducing a high immune-response compared to
other species [28, 96, 97, 99].
Knowledge of the inner core region of Bcc LPS is vital in discussing the physico-
chemical and biological properties of the OM [28]. The presence of Ko is consid-
ered as a factor that stabilizes the linkage of Kdo to the glucosamine backbone.
This specific feature prevents hydrolysis of the inner core from lipid A. The role
that Ko might play in the immunostimulatory activity and other biological prop-
erties of LPS remains to be clarified.
Ko residues have also been found in the inner core of Acinetobacter species [100,
101], Yersinia pestis [102], Serratia marcescens [103], and B. caryophylli [104]. In
Acinetobacter species the lipid A and inner core are attached by a Ko-(2→6)GlcN
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linkage instead of a Kdo-(2→6)GlcN linkage found in lipid A of the Bcc, Y. pestis,
and B. caryophylli. Unique to Bcc species, is that the Ko residue is always present
(e.g. L-Ara4N), whereas in the other species for a fraction of LPS the Kdo residue
is substituted with another Kdo. Therefore, it might be that the introduction
of a Ko residue is a modification strategy in non-Bcc Gram-negative bacteria.
This feature, as for L-Ara4N [98], suggests that the enzymes involved in Ko
biosynthesis and incorporation are constitutively expressed in Bcc. Hence, Ko
biosynthesis enzymes might be potential targets for the future development of
drugs against Bcc.
For the purpose of these studies, the remainder of the introduction will focus on
lipid A biosynthesis, transport and L-Ara4N modifications.
1.4 Lipid A and inner core biosynthesis
Since 1972, it has been known that LPS is synthesized at the inner surface of
the cytoplasmic membrane [105]. Later work on the LPS biosynthetic pathway
suggested that rough LPS (lipid A and core) and the O-antigen are synthesized
and transported independently over the IM, and are ligated at the periplasmic
site of the IM [106].
The first steps towards the elucidation of the lipid A biosynthetic pathway were
the isolation and characterisation of two lipid A precursors, in 1977 lipid IVA of
Salmonella typhimurium by P. Rick [107], and lipid X (2,3-diacylglucosamine 1-
phosphate) of E. coli in 1981 by Masahiro Nishijima [108]. Since then, the lipid A
pathway has been elucidated and excellent reviews are available [81, 84, 87, 109].
The lipid A pathway, also called the Raetz pathway, has been mainly charac-
terised by Christian Raetz and collaborators, using E. coli and S. typhimurium
as model organisms. The biosynthesis appears to be highly conserved among
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Gram-negative bacteria and nine constitutive enzymes are involved (Figure 1.5).
Of the nine enzymes in E. coli, LpxA, LpxC, and LpxD are soluble proteins,
LpxB and LpxH are peripheral membrane proteins, and LpxK, KdtA, LpxL, and
LpxM are inner membrane proteins. The active sites of all (structurally char-
acterised) proteins have been found to be facing the cytoplasmic surface of the
inner membrane [85].
UDP-N -acetylglucosamine (UDP-GlcNac) is, as for peptidoglycan biosynthesis,
the first precursor of the pathway. It is reversibly acylated at position 3 by LpxA.
LpxA requires the thioester R-3-hydroxyacyl-acyl carrier protein (ACP) as the
obligate fatty acyl chain donor [110]. The length of the incorporated fatty acyl
chain differs between species and varies between C10 and C14 [111, 112] Though
it was published as the ”first committed step of the pathway” [110], the reaction
has an unfavorable equilibrium constant (Keq= ∼0.01) [113].
The second step is catalysed by LpxC, which deacetylates UDP-(3-O-(R-3-hydroxy-
acyl))-N -acetylglucosamine (UDP-monoacyl-GlcNac) at position 2 and is the ac-
tual first ”committed” or irreversible step of the pathway. UDP-monoacyl-GlcN,
which allows addition of a second fatty acyl chain, and free acetate are the prod-
ucts of this reaction [114].
LpxD adds an N -linked fatty acid to the free amino group, generated by LpxC,
and forms UDP-2,3-diacyl-GlcN. Like LpxA, LpxD also requires an acyl-ACP
donor [115].
Thereafter the synthesis splits in two. The pyrophosphate linkage of part of the
UDP-diacyl-GlcN intermediates is cleaved by LpxH, yielding 2,3-diacylglucosamine
1-phosphate (lipid X) and UMP [116]. The other part remains uncleaved.
LpxB, brings the two pathways back together, and is responsible for the conden-
sation of one lipid X molecule with one UDP-diacyl-GlcN molecule which forms
the typical acylated β-1′-6 linked disaccharide of glucosamine [117].
LpxK phosphorylates the 4′-position of the disaccharide, using ATP as a co-
























































The last three steps of the lipid A biosynthesis are catalyzed by KdtA, LpxL and
LpxM. KdtA is a 3-deoxy-D-manno-octulosonic acid (Kdo) transferase [119, 120].
KdtA is an enzyme whose activity differs between species. It can be monofunc-
tional, adding one Kdo residue to lipid IVA, as reported for Haemophilus in-
fluenza [121], bifunctional, e.g. in E. coli [119], Acinetobacter haemolyticus [122],
and B. cepacia [95], trifunctional, as in Chlamidia trachomatis [123], or even
tetrafunctional, as in Chlamidia psittaci [124]. However, the addition of two Kdo
sugars seems to be most common. The Kdo residues form the inner core of LPS
and the outer core/ heptose region is connected to position 7 of the first Kdo
residue.
LpxL and LpxM complete the lipid A biosynthesis by the addition of two sec-
ondary fatty acyl chains at the 2′ and 3′ positions. Like LpxA and LpxD, they
use acyl-ACP thioesters as substrate donors. Unlike LpxA and LpxD, ACP can
be replaced with coenzyme A thioesters [125, 126]. Depending on the bacterial
species, LpxL and LpxM require prior attachment of the Kdo residues to the lipid
substrate, or can take place when the Kdo residues are not present [127].
As mentioned earlier, and in contrast to E. coli, in the lipid A of Bcc species and
several other species, one Kdo residue is replaced by a Ko residue in the inner core.
It remains unclear how Ko is synthesized and incorporated into the lipid A. There
are two possible ways: 1) the Kdo transferase adds two Kdo residues of which
one is hydroxylated afterwards at position 3 by an unknown monooxygenase; 2)
Ko is synthesized in the cytoplasm and transferred in an independent manner.
However, previous studies of the Kdo transferases, of the Ko containing species,
B. cepacia ATCC 25416 [95], A. haemolyticus and A. baumannii, [122] has shown
these enzymes to be bifunctional. This evidence, together with the finding that
the inner core of Acinetobacter is linked to lipid A through Ko, supports the
hypothesis that a hydroxyl group is introduced after the addition of two Kdo
residues to lipid A.
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1.4.1 LpxC (UDP-3-O-acyl-GlcNac deacetylase)
The LPS biosynthesis pathway provides a promising target for the development
of new antibiotics against multi-drug resistant Gram-negative pathogens [128].
In recent years one specific target that has attracted interest is LpxC. The rea-
sons for this attention include 1) LpxC catalyses the first committed step in the
lipid A biosynthesis pathway and is necessary for viability; 2) LpxC is a metal-
loenzyme and can, like Zn2+- dependent hydrolases, be effectively inhibited by
hydroxamate-containing compounds; and 3) LpxC has no eukaryotic homologs,
thus reducing the hazards of human toxicity of LpxC-specific drugs.
Figure 1.6: Enzymatic reaction catalyzed by LpxC. Adapted from [114].
LpxC removes the acetyl moiety from the substrate UDP-3-O-acyl-GlcNac, gen-
erating a free acetate and UDP-3-O-acyl-GlcN (Figure 1.6). LpxC requires a
single Zn2+ ion in the active site for enzyme activity [129]. From sequence analy-
sis it has not been possible to identify common Zn2+ binding motifs (e.g. HXXE,
HXXEH or HEXXH) in any LpxC enzyme of different species, therefore single
amino acid substitutions in E. coli of 10 conserved residues found in 11 species
were made to identify groups that coordinate Zn2+. Four residues that could
coordinate Zn2+ were identified during this study, His79, His238, Asp242, and
His265 [130]. Recently, another study by Hernick and colleagues has suggested
that LpxC has been misclassified as a Zn2+-dependent enzyme due to enzymatic
assays and crystallography being carried out under aerobic conditions. It is six-
to nine- fold more active with the redox-sensitive metal ion Fe2+ bound under
anaerobic conditions [131]. As previously found for Zn2+ [129], up to 1 M Fe2+/
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1 M enzyme activates LpxC, whereas a further increase of [Fe2+] inhibits activ-
ity [131].
In 2003, the structure of Aquifex aeolicus LpxC was elucidated by nuclear mag-
netic resonance (NMR) and x-ray crystallography (Figure 1.7) [132]. In addition
to the structure of the enzyme alone, there are also structures available of the
enzyme in complex with myristic acid [132, 133], UDP [133, 134], and with several
enzyme inhibitors [135, 136]. Furthermore, the crystal structure of P. aeruginosa
LpxC complexed with an inhibitor has been elucidated [137].
Figure 1.7: Crystal structure of A. aeolicus LpxC. A) LpxC space fill (red= α-
helices, yellow= β-sheets) with UDP and myristic acid bound. UDP is bound
close to the active site. Myristic acid is located in the hydrophobic passage of
the protein. The active site residues, His79, His238, Asp242, and Glu78 are
highlighted. B) LpxC cartoon, with α-helices and β-sheets. C) The active site/
metal binding site of LpxC. The structures were made using PyMoL and PDB
file 2IER was taken from http://www.rcsb.org [132, 133].
A. aeolicus LpxC belongs to the α+β class of proteins and consists of two topolog-
ically similar domains linked by 16 residues. Both domains contain a five-stranded
β-sheet and two α-helices. The active site cleft is sandwiched between the two do-
mains and is flanked by the two small subdomains, a βαβ and a βββ domain. A
∼15-Å-long hydrophobic tunnel leading out of the active site is present where the
aliphatic tail of the fatty acid of the substrate binds and stabilizes the βαβ subdo-
main conformation. The crystal structure of LpxC with Zn2+ bound showed that
the metal, located in the active site, is coordinated by His79, His238, Asp242, and
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a water molecule [132]. Glu78 probably serves as a general base in the deacetylase
reaction. It abstracts a proton from the Zn2+-bound water molecule, generating
a hydroxide ion which is capable of a nucleophilic attack on the carbonyl group
of the substrate by the hydroxide ion (Figure 1.8). A tetrahedral intermediate is
then formed and the amino group accepts a proton from Glu78, thereby cleaving
the amide bond, producing acetate and UDP-3-O-acyl-GlcN [132, 138]. There
are different hypotheses whether Glu78 is the only amino acid serving as both
the base and acid or whether His265 and Glu78 act in an acid base pair mecha-
nism [139, 140].
Figure 1.8: Proposed catalytic mechanism of LpxC. Adapted from [132, 138].
LpxC as a drug target
Theoretically, an antibiotic that is functional against LpxC enzymes from a wide
range of Gram-negative bacteria should interact with the conserved features
among the LpxCs of different organisms. To identify these conserved features, the
A. aeolicus LpxC sequence was aligned with thirty LpxCs from different species.
A. aeolicus is a thermophilic bacterium (growing at 95 oC), considered as one of
the earliest diverging eubacteria on the evolutionary tree. With the help of the
high resolution structures of this enzyme, several compounds (Figure 1.9 have
been designed and found to inhibit E. coli LpxC, P. aeruginosa LpxC, and/ or
A. aeolicus LpxC [128, 141, 142].
The first LpxC inhibitors designed were hydroxamate containing compounds, such
as L-161,240 and BB-78485. These compounds are active against E. coli LpxC,
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but have little effect on P. aeruginosa [128, 141, 143]. Later, the hydroxam-
ate containing substrate analogue, TU-514, reported to be a potent inhibitor of
E. coli LpxC in vitro. However, TU-514 did not show antibacterial activity due
to its incapability to penetrate the cell wall of Gram-negative bacteria [142].
Figure 1.9: Five potent LpxC inhibitors. Adapted from [128, 141, 142, 144, 145].
Recently, the novel LpxC inhibitor CHIR-090 (N-aroyl-L-threonine), shown in
Figure 1.9, was designed [144]. CHIR-090 has slow, tight-binding characteristics
that act in a time-dependent manner on LpxC [144, 146]. The crystal structure
of the A. aeolicus LpxC-CHIR-090 complex (Figure 1.10) shows that the hydrox-
amate moiety coordinates the catalytic Zn2+ ion and binding is further strength-
ened through interactions with conserved residues in the active site. The biphenyl
acetylene moiety of CHIR-090 inserts into the hydrophobic passage and the mor-
pholine unit can be found in the distal end of the hydrophobic passage [135].
CHIR-090 is capable of penetrating the cell membrane of Gram-negative bacte-
ria and displays promising antibacterial activity against E. coli, P. aeruginosa,
A. aeolicus, and several other Gram-negative bacteria [144, 146]. So far it seems
that, of all hydroxamate containing LpxC inhibitors designed, CHIR-090 is the
most potent inhibitor and might have clinical utility.
Hydroxamate is a functional group that acts as a very good zinc chelator. How-
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Figure 1.10: Crystal structure of A. aeolicus LpxC with the inhibitor CHIR-090
bound. A) LpxC-CHIR-090 complex cartoon. The active site residues are indi-
catied in blue and CHIR-090 in orange. The hydroxamate moiety of CHIR-090 is
facing the active site residues. B) LpxC-CHIR-090 sphere. The biphenyl acety-
lene moiety of CHIR-090 is located in the hydrophobic passage of the enzyme.
PDB file 2JTC was taken from http://www.rcsb.org [135].
ever, due to its activity against many metalloenzymes, compounds containing a
hydroxamate group might display a lack of specificity. Non-specific binding of
an inhibitor to enzymes other than its primarily target, could lead to unwanted
side-effects. Therefore, a new class of LpxC inhibitors is now being explored and
has been patented, in which the hydroxamate group is replaced by a hydantoin.
Compound 22, shown in Figure 1.9, is an example of this new class of inhibitors
and has shown, both in vitro and in vivo, activity against P. aeruginosa [145].
1.5 Aminoarabinose biosynthesis
The mechanism of L-Ara4N modifications and biosynthesis of L-Ara4N has been
extensively studied in E. coli and Salmonella by Christian Raetz and co-workers.
Eight enzymes are involved in the L-Ara4N biosynthesis, transport, and attach-
ment to lipid A (Figure 1.11).
In E. coli the first step is carried out by Ugd, an UDP-glucose dehydrogenase, that
oxidises UDP-glucose to UDP-glucuronic acid [147]. Recently, it has been found
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that P. aeruginosa and B. cenocepacia both contain two genes that encode for
proteins with Ugd activity [148, 149]. The second step is the oxidative decarboxy-
lation of UDP-glucoronic acid by the C-terminal domain of ArnA, yielding UDP-
4-ketopentose (UDP-Ara4O) [147]. The pyridoxal 5′-phosphate (PLP)-dependent
enzyme, ArnB, then transaminates UDP-Ara4O, yielding UDP-β-L-Ara4N [150].
The equilibrium of this transamination is on the side of the ketone, but is shifted
to the amine by a consecutive following reaction, carried out by the N-terminal
domain of ArnA. This domain of the enzyme formylates the freshly formed UDP-
β-L-Ara4N, yielding UDP-L-Ara4-formyl-N (UDP-L-Ara4FN). ArnC, the fourth
enzyme of the pathway, transfers UDP-L-Ara4FN to undecaprenyl phosphate,
releasing UDP [151]. Undecaprenyl phosphate-α-L-Ara4FN is deformylated by
ArnD, and undecaprenyl phosphate-α-L-Ara4N is ready to be flipped over the
membrane [151]. Two proteins are involved in the flipping process, ArnE and
ArnF [152], which form a heterodimer. After arriving at the outer layer of the
IM, L-Ara4N is attached to lipid A at the 4′-phosphate by ArnT [153].
Figure 1.11: E. coli L-Ara4N biosynthesis, transport, and attachment to lipid A.
Adapted from [152].
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In E. coli and Salmonella, and unlike the genes involved in lipid A biosynthe-
sis, the genes involved in L-Ara4N, except for Ugd, are located in an operon,
called the arn operon (Figure 1.12) [147, 154]. Originally, the arn gene operon
was called the pmr locus, due its direct link to PmxB resistance. The operon is
not continuously expressed in E. coli and Salmonella, but is induced in response
to the local environment (e.g. presence of AMPs, limiting Mg2+ conditions),
through the activation of the two-component regulatory system PmrA-PmrB. In
these two species, gene knock-outs or deletions of any of the genes in the arn
operon does not effect viability but leads to loss of PmxB resistance [154, 152].
The putative arn gene homologues were recently identified in B. cenocepacia
J2315. Though the organization is different than in E. coli and Salmonella, the
putative homologues of the arn genes of B. cenocepacia J2315 are also located to-
gether in an operon (Figure 1.12) [98]. To date, the activity of any of the putative
genes in the operon has not been proven; however, analysis of the operon suggests
several differences in the enzymes involved in the pathway between B. cenocepa-
cia and other well studied species. ArnA is a bifunctional enzyme in E. coli and
Salmonella, where the C-terminus of the enzymes catalyzes the second step of the
pathway and the N-terminus catalyzes the fourth step of the pathway. In con-
trast, in B. cenocepacia, both reactions appear to be carried out by two proteins
encoded by separate genes, ArnA1 and ArnA2. Furthermore, the genes encoding
the heterodimer flippase ArnE and ArnF, could not be identified in B. cenocepa-
cia. By low sequence homology to ArnE/ ArnF it is thought that the ArnG gene
in the B. cenocepacia arn operon encodes a putative flippase.
In contrast to E. coli and Salmonella, the putative arn genes are necessary for
viability in B. cenocepacia [98] and therefore the enzymes involved in L-Ara4N
biosynthesis are potential targets for the development of anti-Bcc drugs.
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Figure 1.12: Genetic organization of the Arn operon found in: (A) E. coli and
Salmonella [152]; and B the putative Arn operon of B. cenocepacia J2315 [98].
1.5.1 ArnB (UDP-Ara4O aminotransferase)
ArnB is an aminotransferase that converts UDP-Ara4O into UDP-Ara4N, using
PLP as a co-factor. Like most enzymes that use PLP as a co-factor [155], ArnB
acts on amino acids, preferably L-glutamate [150]. The crystal structure of S. ty-
phimurium ArnB has been published, and together with biochemical analysis of
the protein, the full reaction mechanism of the enzyme (Figure 1.13) was pro-
posed [156]. The crystal structure of the holo-form of the homodimeric ArnB
shows that the co-factor PLP is covalently attached to the amino group of a
conserved Lys188 residue via a Schiff base. This holo-form of the protein is also
known as the internal aldimine (E-PLP). The reaction consists of two half reac-
tions.
In the first half an external aldimine is formed by the displacement of the lysine-
PLP aldimine bond by the L-glutamate-PLP aldimine bond. Then formation of
the quinonoid intermediate takes place by deprotonation in the α-position of L-
glutamate, followed by the reprotonation of the quinonoid species to generate ke-
timine 1. The ketimine is hydrolyzed, giving the reduced cofactor pyridocamine-
5′-phosphate form (E-PMP) and free α-ketoglutarate.
The second half of the reaction starts with the binding of UDP-Ara4O to E-PMP,
generating ketimine 2. Next, ketimine 2 is deprotonated in the α-position from
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Figure 1.13: Catalytic mechanism of Salmonella ArnB. The first- and second-
half reaction are shown. Adapted from [156].
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UDP-Ara4O, forming quinonoid 2. This intermediate is reprotonated to the ex-
ternal aldimine 2, which is then hydrolyzed, regenerating the E-PLP form and
UDP-L-Ara4N.
Figure 1.14: The active site of S. typhimurium ArnB. Shown are the E-PLP state,
the E-PMP state, and with cycloserine bound in the active site. PDB file 1MDZ
was taken from http://www.rcsb.org [156]
Interestingly, the ArnB enzyme of S. typhimurium can be inhibited by L-cycloserine
(LCS, 4-amino-3-isoxazolidone). The crystal structure of ArnB with LCS in the
active site (Figure 1.14) shows that LCS binds to the co-factor by replacing the
PLP-lysine aldimine bond by a LCS-PLP amine bond [156].
Cycloserine (CS) is a cyclic amino acid mimic and two enanthiomers exist, D-
cycloserine (DCS, also known as Seromycin) and L-cycloserine (LCS). DCS is
a well known but now little used antibiotic known to inhibit a wide range of
PLP-dependent enzymes. Today, it is primarily used as a second line of defence
to treat multiple drug-resistant Mycobacterium tuberculosis infections, as well as
some neurological disorders. In M. tuberculosis the primary targets of DCS are
the PLP-dependent enzymes D-alanyl-D-alanine ligase and D-alanine racemase,
both involved in peptidoglycan synthesis.
1.6 Lipid A transport
All three structural domains of LPS, the O-antigen region, the core, and lipid A
are synthesized at the cytoplasmic site of the IM. The O-antigen and lipid A
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are transported independently to the periplasmic site of the IM, where the two
domains are ligated by an enzyme called WaaL [81]. The outer core and O-antigen
sugars are transported over the IM by the O-unit transporter Wzx [157, 158].
Polymerization of the sugar units takes place in the periplasm by Wzx polymerase,
before ligation to lipid A [81]. Though the lipid A biosynthesis pathway has been
very well studied, the mechanism by which lipid A or LPS in its full length
(lipid A plus the core and O-antigen domain) is transported to the OM is less
well understood [159, 160].
The first step in the movement of lipid A to the OM is the translocation from
the site of synthesis, the inner leaflet of the IM, to the outer leaflet of the IM.
It is generally believed that this process is mediated by the ABC transporter
MsbA. This transporter belongs to the ATP-binding cassette superfamily, and is
essential for viability. E. coli conditional MsbA mutants accumulate lipid A and
phospholipids in the IM [161], and lipid A is capable of modulating MsbA activ-
ity [162]. E. coli late acyl-transferase (LpxL) mutants accumulate tetra-acylated
lipid A in the cytoplasm and are greatly impaired in cell division. Overexpression
of MsbA in those mutants restores normal growth [163]. It has never been proven
that MsbA can transport lipid A, but recently it has been shown to transport
phospholipids and other lipid species across the IM [164].
In the last few years, seven other lipopolysaccharide transport (Lpt) proteins es-
sential for the transport of lipid A have been identified. A schematic presentation
of the location of those seven proteins is shown in Figure 1.15. After lipid A is
flipped across the IM by MsbA, it has to be extracted from the phospholipid
bilayer, a process that requires energy. The lack of an obvious energy source
in the periplasm makes the mechanism of trafficking hard to understand. Four
proteins, LptB [165], LptC [166], LptF, and LptG [167] form a complex in the
IM [168] and are most likely involved in the extraction [106]. LptB is located at
the cytoplasmic site of the IM and exhibits ATP hydrolytic activity [168, 169].
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LptF and LptG are both IM proteins that most likely form the transmembrane
components of the ABC transporter co-operating with LptB. LptC is found at
the outer leaflet of the IM and encodes one membrane spanning domain [166].
The structure of LptC has been solved very recently and LptC can bind lipid A
in vitro [170]. However, the exact function of the complex remains to be clarified.
The trafficking of lipid A through the periplasm to the OM is most likely mediated
by LptA [165]. LptA is a soluble periplasmic protein [165] that has been shown
to bind lipid A in vitro [171]. Furthermore, LptA can displace lipopolysaccharide
from LptC in vitro [170].
Two other proteins are involved, LptD [172, 173] and LptE [174]. Both pro-
teins are located in the OM and form a 1:1 complex [175]. There are two classes
of proteins in the OM, β-barrel proteins and lipoproteins [78]. LptD is a β-
barrel protein and LptE is a lipoprotein. LptE has been shown to bind LPS in
vitro [175]. As for the other Lpt proteins, the mechanism of operation of the
LptD/LptE complex is unknown.
Figure 1.15: Schematic representation of the proteins involved in lipid A traffick-
ing from the cytoplasm to the OM in E. coli and two models of lipid A transport
across the membrane. Adapted from [106].
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Two models exist for lipid A trafficking and the proteins involved, the soluble
intermediate model and the the trans-envelope complex model (Figure 1.15). In
the first model, LptA is a soluble protein that acts as a chaperone, and trans-
ports lipid A from the LptBFGC IM complex to the OM LptDE complex [106].
This model looks fairly similar to lipoprotein transport over the IM to the OM.
Lipoproteins are transported by the Lol system, where a complex formed of Lol-
CDE forms the IM ABC transporter. LolA has the periplasmic chaperone func-
tion, which mediates trafficking through the periplasm and binds to the LolB
receptor at the OM [176].
In the trans-envelope complex model, multiple LptA proteins bridge the periplasm,
connecting the IM LptBFGC complex to the OM LptDE complex [160, 106]. The
first proof of this model was published in 2005, before the LptA protein was iden-
tified. It was shown that, in contrast to lipoproteins, newly synthesized LPS could
not be released from spheroplasts upon addition of periplasmic extracts [177]. In
2008, the crystal structure of LptA was published, and though the protein is iden-
tified as a monomer by size-exclusion chromatography, it crystallizes as a fibre in
the presence of LPS [178]. Recently, it has been shown that all seven Lpt proteins
can be co-purified as a complex suggesting they interact directly, a finding that
supports the trans-envelope complex model [175].
LptA (Lipopolysaccharide transport protein A)
LptA, the soluble periplasmic protein shown to bind lipid A of E. coli, is a 185 aa
protein, with a putative signal peptide of 27 aa that enables transport of the
protein to the periplasm [165].
As mentioned above, the structure of E. coli LptA, has been solved (Figure 1.16).
LptA consists, like the human LPS binding protein MD-2, mainly of β-sheets.
LptA has eleven anti-parallel β-sheets that twist 90o over the length of the protein,
forming a hydrophobic cleft. The crystal structures that have up to now been
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(a) (b) (c)
Figure 1.16: Crystal structures of E. coli LptA. A) Spheric image of fibres con-
sisting of LptA proteins crystallized together. B) Cartoon of two LptA proteins,
side view. C) Cartoon of two LptA protein, top view. PDB files 2R19 and 2R1A
were taken from http://www.rcsb.org [178].
solved for E. coli LptA do not contain LPS [178]. The structure of MD-2 on the
other hand, has been solved recently with LPS bound and shows that the fatty
acids of LPS bind to the MD-2 hydrophobic β-sheet pocket [71]. It might be
that, as for MD-2, only the fatty acids bind in the hydrophobic cleft of LptA, a
hypothesis supported by the work of Tran et al. [171], who showed that LptA is
capable of binding smooth-LPS, Kdo2-lipid A and lipid IVA. Figure 1.16 A shows
eight LptA proteins forming a fiber. Interestingly, this co-crystallization only
occurred when induced with either smooth- or rough- LPS. When not triggered
by LPS, only two proteins co-crystallized, as illustrated in Figure 1.16 (b and c).
LptB (Lipopolysaccharide transport protein B)
LptB belongs to the superfamily of ABC-transporters, and in E. coli, the LptB
gene is located immediately downstream of LptA. In a general study on protein
complexes of the E. coli IM and OM, LptB was initially described to be associated
to the IM [179]. Later, purified LptB was found to form a complex with LptF and
LptG [168, 169]. ATP-hydrolysis by LptB could be observed after purification.
49
Though some ATP-ases can be activated or inhibited by their substrate, LptB
activity is not affected by the presence of smooth-LPS or Kdo2-lipid A [168].
E. coli LptB is capable of hydrolyzing ATP, UTP, GTP and CTP, but showed a
clear substrate preference for ATP [169].
LptB recently has received renewed interest as a target for new antimicrobial
agents. As an aid in these studies, a high-throughput assay for activity was
recently developed [169]. Two commercially available kinase inhibitor libraries
(244 compounds) have been tested against E. coli LptB and two potent inhibitors
have been highlighted (Figure 1.17). Furthermore, in a previous study [168], the
well known ATP-ase inhibitor, orthovanadate, was shown to be inhibitory against
E. coli LptB. Although, all three compounds inhibit LptB in vitro, in vivo, killing
assays have not been succesful to date [169].
Figure 1.17: Two published E. coli LptB inhibitors. Adapted from [169].
1.7 Aims
Species belonging to the Bcc are not harmful to healthy individuals, but can
cause life-threatening lung infections in people suffering from CF. The Bcc are
amongst the most antimicrobial-resistant pathogens encountered in human infec-
tions, making successful treatment of the infection virtually impossible. Once the
CF lung gets infected by the Bcc, it can cause the lethal ”Cepacia syndrome.” In
this thesis, I focused my research on one of the virulence factors, lipid A, which
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might cause ”Cepacia syndrome,” and antimicrobial drugs that target lipid A
biosynthesis.
This thesis is divided into three sections:
1. CHIR-090 activity against the Bcc;
2. D-cycloserine activity against the Bcc;
3. L-Ara4N specificity of lipid A transport.
The aim of the first section (CHIR-090 activity against the Bcc) was to study
the effects of specific inhibitors of the enzymes involved in lipid A biosynthesis
against the Bcc. To study this, I used the most potent LpxC inhibitor published
to date, CHIR-090. A second aim was to investigate the species- and strain-
specific susceptibility towards CHIR-090.
The aim of the second section (D-cycloserine activity against the Bcc) was to
study the potential use of the PLP-dependent enzyme inhibitors D-cycloserine
and L-cycloserine in the treatment of Bcc infections. An additional aim was to
study B. cenocepacia ArnB as a drug target, since this enzyme is necessary for
viability.
The aim of the last section (L-Ara4N specificity of lipid A transport) was to
improve the understanding of why L-Ara4N is necessary for viability in B. ceno-
cepacia but not in other Gram-negative bacteria. To do so, I decided to study
two proteins involved in lipid A transport, LptA and LptB.
The work presented here constitutes one of the first research projects on the
Bcc enzymes involved in lipid A biosynthesis and transport. Since lipid A is an
important virulence factor and enzymes involved in biosynthesis and transport of
this molecule are necessary for viability, it offers an important target for research.
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Chapter 2
The activity of the Lipid A
Biosynthesis Inhibitor CHIR-090
against the Bcc
Part of this chapter was published:
Bodewits K., Raetz C. R., Govan J. R., Campopiano D. J. Antimicrobial activity of
CHIR-090, an inhibitor of lipopolysaccharide biosynthesis, against the Burkholderia
cepacia complex. Antimicrobial Agents and Chemotherapy (2010), 54, 3531-3533.
The discovery and introduction of antimicrobial drugs around the 1930s, led to
an era in which millions of people were saved from the fatal effects of bacterial
infections. Before the availability of antimicrobial agents, hospitals were filled
with patients with tuberculosis, pneumonia, rheumatic fever, and many other
diseases caused by pathogenic bacteria. However, from the 1930s onwards the
wards were mainly filled with patients with diseases that are not caused by bac-
teria, such as cancer, diabetes and heart problems [180]. In the 1980s, many
researchers, clinicians, and pharmaceutical companies thought that after nearly
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half a century of increasing control of microbial diseases, the problem of bacte-
rial infections has been overcome, and research tended to focus on controlling
fungi- and viral- infections [181, 182]. However, in the 1990s, people were con-
fronted with a world-wide re-emerge of bacterial infections which could not be
treated successfully or not as easily as before. The most important reason for
this phenomenon is the acquisition of antibiotic-resistance genes by pathogenic
bacteria, which coincides with a reduction in the discovery of new antibiotics with
novel activity. The rapidity of the acquisition of the antibiotic-resistance genes
by pathogenic bacteria increased after the 1980s due to increased air travel, the
higher frequency of invasive surgery, a higher number of immunocompromised
individuals in the population, and the increased survival of patients with chronic
debilitating diseases, such as CF [182]. Hence, for the last ∼30 years, the options
for treatment of bacterial diseases is have reduced and there is now an urgent
need for new agents with novel antimicrobial activity against both existing and
emerging bacterial pathogens.
The LpxC inhibitor CHIR-090
Figure 2.1: The LpxC inhibitor CHIR-090 (N-aroyl-L-threonine). Adapted from
[144].
The lipid A biosynthesis pathway has been recognized as an attractive target for
new agents design to treat infections caused by Gram-negative bacteria [128, 181].
The most potent inhibitor of this pathway found so far is the synthetic antibiotic
CHIR-090 (Figure 2.1). This antibiotic has been shown to be a slow, tight-
binding inhibitor of the purified LpxCs from different species [135, 144, 146]
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and displayes good antimicrobial activity against several Gram-negative bacte-
ria, including E. coli and P. aeruginosa [146]. In this chapter, the potential of
antibiotics targeting lipid A biosynthesis to treat Bcc infections is explored, using
CHIR-090 as a model antibiotic (kindly provided by Professor C. R. H. Raetz,
Duke University, USA).
2.1 CHIR-090 against the Bcc
To assess the antibacterial activity of CHIR-090 against B. cenocepacia and
B. multivorans, the main Bcc species recovered from CF sputum, a disc diffu-
sion test was carried out. This is a commonly-used assay, where an agar plate
is inoculated uniformly with the bacteria of interest. Then, a filter paper disk
impregnated with the antibiotic is placed onto the plate so that the antibiotic
can diffuse through the agar. When grown overnight, the bacteria will grow con-
fluently on top of the plates, with or without zones of bacterial growth inhibition
around the antibiotic disk. The diameter of the inhibition zone depends on the
susceptibility of the bacteria, the concentration of antibiotic, and the speed of
diffusion of the antibiotic.
A panel of six strains was assembled, including two positive control strains. The
control strains E. coli K-12 (MG1655) and P. aeruginosa (PAO1) were used based
on previously published work in which CHIR-090 was shown to be active against
those strains [146]. One B. multivorans strain (C5393) and three B. cenocepa-
cia strains (J2315, K56-2, and SAL-1) were included. The three B. cenocepacia
strains belong to the clonally-related ET12 lineage and were chosen for their dif-
ference in LPS profile and their relevance in epidemic outbreaks. B. cenocepacia
J2315, the strain responsible for an epidemic outbreak in Edinburgh [26], pro-
duces rough LPS. B. cenocepacia K56-2, a Canadian CF isolate [63], produces
smooth LPS. B. cenocepacia SAL-1 is a genetically manipulated strain derived
























































































has been shown that clear zones of inhibition of CHIR-090 against P. aeruginosa
could be obtained using 10 µg/disc [146]. Therefore it was decided to carry out
a disc diffusion assay with discs containing CHIR-090 concentrations in the same
range (e.g. 0, 1, 5, 10, 20, and 40 µg/disc). The results for 1, 10, and 40 µg
against the six strains are shown in Figure 2.2.
The growth of E. coli and P. aeruginosa was clearly inhibited by the lowest
amount of CHIR-090 (1 µg), whereas B. multivorans was inhibited by 10 µg
containing discs. In contrast, growth of all three B. cenocepacia strains was not
inhibited with discs containing 40 µg CHIR-090. In further tests, these strains dis-
played resistance even when discs containing 100 µg were used (data not shown).
Analysis of my data suggests that there is no correlation between CHIR-090
growth inhibitory activity and the LPS profile of individual strains. By using
the three B. cenocepacia strains K56-2 (smooth LPS), J2315 (rough LPS), and
SAL-1 (deep-rough LPS), I can conclude that the presence of an O-antigen or
complete core region does not affect the susceptibility to CHIR-090.
Despite the fact that species of the Bcc are genetically closely related, growth of
B. multivorans could be inhibited, whereas growth of B. cenocepacia could not.
This unexpected result lead us to subsequently test CHIR-090 activity against
more Bcc species.
I used the disc diffusion assay to determine the sensitivity to CHIR-090 of the
Bcc reference panels [35, 38], consisting of 45 Bcc strains1 representing the first
nine reported Bcc species (Table 2.1).
Prior to the assay, DNA of all 45 Bcc strains was isolated and a recA/RFLP
analysis was performed to confirm the identity of the strains (Appendix A.1).
Further studies were only carried out with the recA positive strains.
A concentration of 40 µg CHIR-090 was used throughout the study. The results
1The B. cenocepacia K56 derivative SAL-1 was also included in this study, but does not
belong to the Bcc reference panel
56
Table 2.1: CHIR-090 sensitivity of the Bcc reference panel and the presence of
the LpxC2 gene. L2 = presence of LpxC2; S = sensitivity to CHIR-090; IZ =
diameter of inhibition zone (mm).
Strain L2 S (IZ) Strain L2 S (IZ)
B. cepacia (I) B. dolosa (VI)
ATCC25416 + - - AU0645 - + 18
ATCC17759 + - - CEP021 - + 24
CEP509 + - - E12 - + 23
LMG17991 STM1441 - + 21
B. multivorans (II) B. ambifaria (VII)
C5393 - + 20 AMMD - + 23
LMG13010 - + 14 ATCC53266 - + 24
C1575 - + 15 CEP0996 - + 22
CF-A1-1 - + 22
JTC - + 23
C1962 - + 24
ATCC17616 - + 17
249-2 - + 26
B. cenocepacia (III) B. anthina (VIII)
J2315 + - - W92 - - -
BC7 + - - C1765 - + 13
K56-2 + - - J2552 - - -
C5424 - + 19 AU1293 - + 10
C6433 + - -
C1394
PC184 - + 18
CEP511 + - -
J415 - + 21
ATCC17765 + - -
SAL-1 + - -
B. stabilis (IV) B. pyrrocinia (IX)
LMG14292 + - - ATCC15958 - + 20
C7322 + + 14 ATCC39277 - + 22
LMG14086 + - - BC011 - + 23
LMG18888 + - - C1469 + - -
B. vietnamiensis (V)
PC259 - + 26
LMG16232 - + 23
FC441 - + 9
LMG10929 - + 23
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of the disc assay against the whole panel are summarised in Table 2.12; clearly-
observed zones are reported as (+) and no growth inhibition as (-). For the
(+) strains, the diameter of the inhibition zones are given. It was clear at this
stage that despite the close taxonomic relationship of all Bcc species, individual
isolates displayed remarkable differences in their susceptibility to CHIR-090 even
within a single species. For example, of the eight B. cenocepacia (III) strains, two
(C5424 and PC184) were sensitive and six resistant. Moreover, three of the highly
transmissible ET12 lineage (J2315, K56-2 and BC-7) were resistant, and C5424
was sensitive. All representative strains of B. multivorans, B. vietnamiensis,
B. dolosa and B. ambifaria showed sensitivity to CHIR-090.
2.1.1 CHIR-090 against B. multivorans
B. multivorans, one of the most prevalent Bcc species recovered from the CF
lung [59], could be inhibited by CHIR-090. Encouraged by this finding, the
MICs were determined for all B. multivorans strains of the panel (Table 2.2). In
the absence of published guidelines to determine MICs for the Bcc, the decision
was made to use the internationally-accepted BSAC methodology [184] for other
Gram-negative pathogens. As described in the BSAC guidelines, the quality con-
trol strains P. aeruginosa ATCC27853, P. aeruginosa ATCC10145, and E. coli
ATCC25922 were used. Due to a lack of a suitable antibiotic active against all
members of the Bcc, PmxB was used as a control for activity against P. aerug-
inosa and E. coli. PmxB was used as a positive control for the uniquely-high
resistance of B. multivorans (and all other members of the Bcc).
The CHIR-090 MICs for B. multivorans were strain-dependent, and ranged from
0.1 to >100 µg/ml. CHIR-090 was particularly active against B. multivorans
249-2, previously noted for its resistance to beta-lactams (including the ability
to use penicillin G as a sole nutrient) [52], whereas it was not active against the
2Table 2.1 also presents results which will be discussed in the next section of this chapter
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Table 2.2: MIC values (µg/ml) of CHIR-090 and polymyxin B (PmxB) against,
E. coli, P. aeruginosa, and B. multivorans a panel of strains (antibiotic concen-
tration ranged from 0 to 100 (µg/ml).
Strain Source/reference CHIR-090 PmxB
E. coli
ATCC25922 ATCC 0.05 0.78
P. aeruginosa
ATCC27853 ATCC 0.78 3.13
ATCC10145 ATCC 0.78 3.13
B. multivorans
C5393 Vancouver CF clinic [185] 3.13 >100
LMG13010 Belgium CF clinic [186] >100 >100
C1575 Glasgow Epidemic [60] 12.5 >100
CF-A1-1 Cardiff CF clinic [187] 1.56 >100
JTC CGD patient [188] 1.56 >100
C1962 Brain abscess [189] 3.13 >100
ATCC17616 Environmental strain [47] 6.25 50
249-2 Derived from ATCC17616 0.10 >100
B. multivorans type strain isolated from a Belgian clinic [36]. The low MICs for
most B. multivorans highlights the potential of CHIR-090 against B. multivorans.
2.2 Species and isolate specific susceptibility or
resistance
To explore the species and strain-specific susceptibility to CHIR-090, a BLAST
search was carried out for putative LpxC genes present in the available Burkholde-
ria genomes (Figure 2.3, www.burkholderia.com). Sequence analysis revealed
that the annotated LpxC genes are highly conserved and display high sequence
homology to LpxCs from organisms such as P. aeruginosa and E. coli ; thus, the
resistance of most B. cenocepacia strains against CHIR-090 in contrast to the
susceptibility of B. multivorans could not be explained by differences in the se-
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                    1                                               50
B. cenocepacia  (1) MLKQRTIKSIVKTVGIGVHSGRKIELTLRPAAPGTGIVFSRVDLPTPVDI
B. multivorans  (1) MLKQRTIKSIVKTVGIGLHSGRKVELTLRPAAPGTGIVFSRVDLPTPVDI
                             
                    51                                             100
B. cenocepacia  (51)PASAMSIGDTRLASVLQKDGVRVSTVEHLMSACAGLGIDNLYVDVTAEEI
B. multivorans  (51)PASAMSIGDTRLASVLQKDGARVSTIEHLMSACAGLGIDNLYVDVTAEEI
                   
                    101                                            150
B. cenocepacia (101)PIMDGSAATFVFLIQSAGIEEQNAPKRFIKVKKPVEIRDGDKFARLDPYF
B. multivorans (101)PIMDGSAASFVFLIQSAGIEEQNAPKRFIKVKKPVEVRDGDKFARLDPFF
                    




                    201                                            250
B. cenocepacia (201)REIGLARGGSMDNAIVLDEYRILNNDGLRYDDEFVKHKMLDAIGDLYVIG
B. multivorans (201)RELGLARGGSMDNAIVLDEYRILNNDGLRYDDEFVKHKMLDAIGDLYVVG
           
                    251                                            300
B. cenocepacia (251)HPLLASYTAYKSGHGLNNALLRELLAHEDAYEIVTFDDPQAAPKGFAFDA
B. multivorans (251)HPLLASYTAYKSGHGLNNALLRELLAHEDAYEIVTFDDPQAAPSGFAFDT
    
                    301
B. cenocepacia (301)QTAFA
B. multivorans (301)QTAFA
                             
Figure 2.3: Sequence alignment of the translated LpxC genes of B. cenocepacia
J2315 (BCAL3455) and B. multivorans ATCC17617 (Bmul2829).
quence differences between the putative LpxC genes in the genome. To illustrate
the high sequence homology between the putative Bcc LpxC genes, an alignment
of the translated genes of B. cenocepacia J2315 and B. multivorans ATCC17617
is shown in Figure 2.3. The two LpxC genes are 95% identical and 98% similar
to each other.
During the Burkholderia genome analysis, I discovered LpxC orthologs in many
species with low amino acid sequence similarity to the well-characterised LpxC
from E. coli. Also, the second putative ORF was annotated in the genomes as
LpxC. For example, in B. cenocepacia J2315, there are two putative ORFs an-
notated as LpxC; BCAL3455 that shows 71% similarity to E. coli LpxC, and
BCAL3219 that shows 44% similarity to E. coli LpxC. In the genome of B. mul-
tivorans ATCC17617, only one putative ORF is annotated as LpxC, namely
Bmul2829, which is 71% similar to E. coli LpxC. I could hypothesise that this
unique LpxC ortholog, found in B. cenocepacia J2315, but not B. multivorans
ATCC17617, might be responsible for resistance to CHIR-090.
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Figure 2.4: Amino acid sequence comparison of LpxC1 (BCAL3455) and LpxC2
(BCAL3219) of B. cenocepacia J2315. Grey-Pink aa, putative active site residues;
blue-green, CHIR-090 binding residues (identified in A. aeolicus) in LpxC1; blue-
red, CHIR-090 binding residues in LpxC2.
Amino acid alignment of the two putative open reading frames (ORFs) found
in B. cenocepacia J2315, BCAL3455 and BCAL3219, also referred to as LpxC1
and LpxC2 respectively, is shown in Figure 2.4. LpxC1 and LpxC2 show 47%
similarity and 29% identity. A Blast analysis was performed, using all microbe
genomes available on the NCBI website (http://www.ncbi.nlm.nih.gov), and it
was found that the presence of LpxC2 is unique to Burkholderia species, but is
not present in all Burkholderia species. Of the Burkholderia species sequenced
so far, B. cenocepacia, Burkholderia sp383, B. pseudomallei, and B. mallei have
a LpxC2 homolog, whereas B. multivorans, B. thailandensis, B. ambifaria, and
B. vietnamiensis lack the second putative LpxC.3
From sequence analysis of the different LpxC enzymes of different species (Ap-
3Burkholderia sp383, B. pseudomallei, B. mallei, and B. thailandensis do not belong to the
Bcc.
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pendix A.2) and the LpxC1 and LpxC2 alignment (Figure 2.4), it would not be
surprising if LpxC2 of B. cenocepacia shows UDP-3-O-acyl-GlcNac deacetylase
activity and at the same time is not inhibited by CHIR-090.
Jackman et al [130] suggested that only 33 amino acids of the LpxCs of 11 diverse
Gram-negative bacteria were conserved within the species. Out of these 33 amino
acids, 27 are present in LpxC2 as well. Furthermore, the four Zn
2+ binding mo-
tif/ active site residues, typical for LpxCs and known to be essential for catalysis,
are present in LpxC2. Barb et al [135] described the structure of the A. aeolicus
Figure 2.5: CHIR-090 bound into the active site of A. aeolicus LpxC. Taken from
[135].
LpxC-CHIR-090 complex and indicated the amino acids involved in CHIR-090
binding (Figure 2.5). Having had a closer look at these essential amino acids,
I concluded that it is not likely that CHIR-090 would inhibit LpxC2. A. aeoli-
cus T179, with which the CHIR-090 threonyl group forms a hydrogen bond, is
replaced by serine in LpxC2, thereby predominantly changing the geometry. A
mutation of this threonine in LpxC of A. aeolicus has already proved to lead
to much less inhibitory activity of CHIR-090 on LpxC [135]. Residue F180 of
A. aeolicus LpxC, with which the methyl group of threonyl of CHIR-090 is in
van der Waals contact is replaced by a tyrosine in LpxC2. The two residues,
H253 and D230, that are both essential for catalysis and might form hydrogen
bonds with the threonyl hydroxyl oxygen of CHIR-090 are both present in LpxC2.
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K227, which is the third potential amino acid to form a hydrogen bond with the
hydroxyl oxygen of CHIR-090, is replaced by an arginine in LpxC2, changing
the hydrogen bonding pattern. Many residues identified as important for the
biphenyl acetylene moiety and morpholine unit insertion in the hydrophobic pas-
sage by forming hydrophobic interactions, are mutated in LpxC2 to either charged
residues or other hydrophobic residues.
Moreover, an arginine residue in LpxC2 replaces G198 of A. aeolicus. A muta-
tion in this glycine to an hydrophilic residue (serine) is found in the CHIR-090
insensitive LpxC of R. leguminosorum as well. For R. leguminosorum LpxC it
was suggested as one of the differences in amino acid sequence that might be
responsible for the decrease in affinity for CHIR-090 by blocking the hydrophobic
passage [135]. Additionally, the putative LpxC2 has a six amino acid insertion
inside the gene not found in any of the LpxCs of other species or in LpxC1 of
B. cenocepacia J2315.
Tertiary protein structure models were made (Figure 2.6) of LpxC1 and LpxC2 us-
ing Swissmodel in which A. aeolicus LpxC was used as a template. The two topo-
logically similar domains, containing a five-stranded β-sheet and two α-helices,
found in A. aeolicus LpxC, could be recognised in both LpxC1 and LpxC2. Both
enzymes contain the four residues known to form the active site, and both have a
long hydrophobic tunnel leading out of the active site suitable for the fatty acid
chain of the substrate. Using real-time PCR, I showed that both genes are ex-
pressed in the B. cenocepacia strains K56-2 and J2315 during exponential growth
(results not shown).
2.2.2 The presence of LpxC2 in the Bcc
To investigate a possible correlation between the presence of the LpxC2 gene and
resistance to CHIR-090, it was decided to continue the study by using the whole




Figure 2.6: Structural models of B. cenocepacia J2315 LpxC1 and LpxC2 which
were generated by Swissmodel and A. aeolicus LpxC (PDB code: 2IER) as a
template. A, A. aeolicus LpxC; B and C, B. cenocepacia J2315 LpxC1 (green)
and LpxC2 (blue) overlaid; D, active site of A. aeolicus LpxC; E, active site of
LpxC1; F, active site of LpxC2.
P. aeruginosa PAO1 control strains.
DNA of all 46 Bcc strains was isolated, and the genomic DNA of all the Bcc
strains were checked for the presence of LpxC2 by PCR, using primers designed
on high homology regions of sequenced Burkholderia species LpxC2 genes. The
presence of PCR products of the different Bcc species is summarised in Table 2.1
and shown in Appendix A.1. All B. cepacia, B. stabilis, and B. anthina strains
possess the LpxC2 gene. Most B. cenocepacia strains, two B. ambifaria strains,
and one B. pyrrocinia (IX) strain also contain the gene.
With only a few exceptions (B. stabilis C7322, B. anthina C1765, and B. an-
thina J2552), a strong correlation was observed between the presence of LpxC2
and resistance against CHIR-090. This supports the hypothesis that LpxC2 can
complement LpxC1, or is responsible for CHIR-090 resistance. B. stabilis C7322
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is the only strain that does contain the LpxC2 gene but is not resistant to CHIR-
090. This could be caused by a natural mutation in the gene, leading to a non-
translated or inactive protein.
For the two B. anthina strains (C1765 and J2552) that show resistance but do
not have the LpxC2 gene, it might be that the concentration tested was too low
to give zones of inhibition. The diameter of the inhibition zones of the other
two B. anthina strains are amongst the lowest. Unfortunately, due to the limited
amount of CHIR-090 I possessed, it was not possible to repeat the disc diffusion
assay with higher concentrations of CHIR-090.
If both LpxC1 and LpxC2 can catalyse the same reaction and have both been
shown to be expressed during exponential growth, then only one of the genes
should be necessary for viability. Therefore, I attempted to create LpxC1 and
LpxC2 knock-out strains. B. cenocepacia strain, K56-2 was used for this study,
since B. cenocepacia J2315 is known to be poor as a recipient in transformation or
conjugation. To create the knock out strains, I first used a pGpΩ plasmid [190],
which inserts itself in the gene of interest, thereby disrupting it. However, re-
peated attempts to knock either of the genes out failed. This might be due to the
fact that other genes lying downstream (in the same operon) as LpxC1 or LpxC2,
are affected by the introduction of the pGpΩ plasmid and are necessary for viabil-
ity, or that LpxC1 and LpxC2 can not fully complement each other and therefore
are both necessary for viability. Subsequently I attempted to create a conditional
LpxC2 mutant using the pSc200 plasmid [98], which inserts itself upstream of the
gene of interest, and introduces a rhamnose inducible promotor PrhaB to drive the
expression of the gene. If LpxC2 is responsible for resistance towards CHIR-090,
Bcc strains should become susceptible to CHIR-090 when LpxC2 is not expressed.
The pSc200 plasmid was transferred to B. cenocepacia K56-2 by triparental mat-
ing and the correct insertion into the chromosome was confirmed by PCR. Next,
a disc diffussion assay with 40 µg CHIR-090 was carried out on minimal media
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supplemented with rhamnose to induce transcription of LpxC2, or with glucose
to suppress transcription. On both media, the B. cenocepacia K56-2 conditional
mutant strain was resistant to CHIR-090 (no inhibition zones), as described for
the wild-type strain in the previous section. A definite conclusion could not be
drawn from this result due to the method used. The pSc200 plasmid introduces
a promotor in front of the gene, enabling partially controlled expression, but
”leaky” expression could still occur. Around the discs containing CHIR-090, a
strong selection pressure might arise for cells that express LpxC2 and ”leaky”
expression alone might be enough to cause resistance. Due to the limited amount
of CHIR-090 available, this experiment was carried out only once.
2.2.3 Cloning and expression of LpxC1 and LpxC2
To characterise the enzymes encoded by LpxC1 and LpxC2, an attempt was made
to clone both genes into expression plasmids for recombinant protein expression in
E. coli. The LpxC1 gene was amplified from genomic DNA of B. cenocepacia J2315
and cloned into the expression plasmid pET22b, giving pET22b LpxC1 J2315.
Several attempts to amplify LpxC2 from genomic DNA failed. Therefore, it was
decided to purchase a synthetic gene encoding LpxC2. This gene was also cloned
into the expression plasmid pET22b, which was named pET22b LpxC2 J2315.
Integrity of the correct plasmids was proven by restriction digests and by se-
quencing of the plasmids (results not shown).
For recombinant LpxC1 and LpxC2 expression, different cell lines, media, and
growth conditions were tried.4 In order to get good LpxC1 expression, E. coli
HMS174 (DE3) competent cells, transformed with pET22b LpxC1 J2315, were
used. Expression was induced with 0.1 mM isopropyl β-D-1-thiogalactopyranoside
(IPTG) for 18 hours at 20 oC (Figure 2.7).
4Cell lines = E. coli HMS174 (DE3) and E. coli BL21 (DE3); media = LB broth and 2YT
broth (with or without the addition of Zn2+); growth conditions = temperature (20 or 37oC,
time (1, 3, 5, and 18 hours), and concentration of IPTG (0.1, 0.5, or 1 mM).
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Figure 2.7: Recombinant LpxC1 expression of by E. coli BL21 (DE3). Lane 1 =
molecular weight marker; lane 2 = after 18 hours of induction.
Disappointingly, LpxC2 was not expressed under any of the conditions tested.
If expression of LpxC2 is toxic to the expression cell lines, cell lysis might take
place. However, the cell lines did not lyse when expression was induced. Also,
the LpxC2 gene does not contain any ”rare” codons which would make it more
difficult for standard expression cell lines to express the protein. Hence, there is
no simple explanation why LpxC2 is not recombinantly expressed in the E. coli
cell lines used.
The enzyme and inhibition assay for LpxC used in previous studies makes use of
enzymatically prepared [α-32P]UDP-monoacyl-GlcNac as a substrate [129, 141,
146]. The substrate and product ([α-32P]UDP-monoacyl-GlcN) can be separated
by thin layer chromatography (TLC) and a phosphor-imager is used to detect
the amount of product formed. Since the Campopiano lab is not equipped to
perform this assay, the assays will be carried out by a collaborator in the lab of
Prof. C. R. H. Raetz (Duke University, USA).
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2.3 Conclusion
The limited options to successfully treat infections caused by resistant bacteria,
and the rapid decline in the introduction of new antibiotics, has led to increasing
interest in the chemical design of new drugs with novel antimicrobial activity.
Enzymes involved in the lipid A biosynthesis pathway, in particular LpxC, have
been recognised as attractive targets for new agents designed to treat infections
caused by Gram-negative bacteria. The most potent inhibitor published so far,
which is capable of inhibiting growth of several Gram-negative species, is the
synthetic antibiotic CHIR-090.
The innate resistance of members of the Bcc to most classes of available antibi-
otics has been linked to their relatively large (∼8-9 Mbp) genomes which contain
multiple antibiotic resistance genes [65]. In addition, the lipid A of the Bcc
species has unique features compared to other Gram-negative bacteria. Unlike
the endotoxins of other Gram-negative bacteria (e.g. E. coli, S. typhimurium,
and P. aeruginosa), the inflammatory activity can not be neutralised by PmxB
[191]. Moreover, the lipid A of the Bcc is always non-stoichometrically modified
with L-Ara4N, and the outer Kdo residue of the inner core is replaced by a Ko
residue. Because of the multi-drug resistance of the Bcc and the uniqueness of
lipid A of the Bcc, I focused my investigation on the potential of antibiotics tar-
geting lipid A biosynthesis to successfully treat Bcc infections, using CHIR-090
as a model antibiotic.
I showed that CHIR-090 can inhibit growth of some Bcc species, including one of
the most prevalent Bcc species, B. multivorans. MICs were determined for eight
B. multivorans strains and were found to be strain-dependent and ranged from 0.1
to >100 µg/ml. Despite the close taxonomic relationship of the Bcc, individual
isolates displayed a remarkable difference in the sensitivity to CHIR-090 even
within a single species. I attempted to understand why some species are resistant
and others susceptible to CHIR-090. It was found that these differences between
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species and strains are not caused by differences in LPS profile (smooth, rough,
and deep-rough LPS). On the other hand, a strong correlation was observed
between the presence of an ORF, encoding a putative LpxC ortholog (LpxC2),
and resistance to CHIR-090. I hypothesised that the two LpxC’s (LpxC1 and
LpxC2) can catalyse the same reaction, but that only LpxC1 is inhibited by
CHIR-090. However, so far it has not been possible to prove that LpxC2 is
responsible for resistance. To confirm this hypothesis, future research could focus
on the in vitro characterisation of LpxC1 and LpxC2. The enzymes of lipid A
biosynthesis, including LpxC, are known to be encoded by single copy genes in
all sequenced Gram-negative genomes [142]. Hence, if LpxC1 and LpxC2 are
capable of catalysing the same reaction in the Bcc, this would also be the first
example of encoding two proteins that catalyse the same reaction within the
lipid A biosynthesis.
To the best of my knowledge, this CHIR-090 study is the first to report an
agent against Burkholderia targeted at the LPS biosynthetic pathway. I showed
that new drugs targeting this pathway have a potential to treat Bcc infections.
However, this potential is likely to be species- and strain-dependent.
New compounds targeting LpxC based on CHIR-090 have proven to be active
and will be patented in future [192]. Unfortunately, CHIR-090 itself does not
seem to be a potential therapeutic agent. CHIR-090 was produced by CHIRON,
a biotech company in California, acquired by Novartis in 2006. According to
Prof. C. R. H. Raetz it was ’dropped’ from CHIRON’s clinical trials for reasons
that were withheld by the company [192].
It has recently been reported that the Bcc display species- and strain-dependent
susceptibility or resistance to biocides with most isolates being highly resistant
to agents that are found in hand-washes and disinfectants [193]. LiPuma and
colleagues reported the in vitro inhibitory activity of a novel nanoemulsion (NB-
401) against a panel of 75 Burkholderia isolates which included 10 B. multivorans
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and 20 B. cenocepacia isolates [194]. The NB-401 MICs were strain-specific and
ranged from 31.2 to 125 µg/ml and <15.6 to 500 µg/ml, respectively. This
suggests that agents specifically interfering with Burkholderia LPS biosynthesis
should be further explored and that they may, possibly in combination with
nanoemulsions, provide a breakthrough in the treatment of CF-related infections.
70
Chapter 3
An Old Antibiotic with a Novel
Use: D-cycloserine fights the Bcc
Part of this chapter will be submitted for publication:
Manuscript in preparation.
As described in the previous chapters, there is an urgent need for antibiotics that
are capable of eradicating Bcc infections, either as monotherapy or in combination
with additional drugs to obtain a synergistic effect. The majority of approaches
to find new drugs has been to search for (entirely) novel compounds. This is
typically being accomplished either by mass screening of natural products to
identify antibiotic activity or by designing ”new” antibiotics, for example CHIR-
090. The approach described in this chapter explores the potential and novel use
of the ”old” antibiotic, cycloserine (CS), to treat Bcc infections.
CS, discovered around 1955, specifically inhibits PLP-dependent enzymes and, as
mentioned in the first chapter, two enantiomers exist, D-cycloserine (DCS) and
L-cycloserine (LCS), illustrated in Figure 3.1. DCS is a natural product that
was isolated from Streptomyces lavendulae and Streptomyces garyphalus [195],
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whereas LCS was originally isolated from Erwinia uredovora [196] and is now
prepared synthetically.
Figure 3.1: The two cycloserine enantiomers, LCS (left) and DCS (right).
DCS (also known as Seromycin) is an ”old” antibiotic used as a second line drug
to treat multiple drug-resistant M. tuberculosis infections as well as neurological
disorders. To my knowledge, neither of the CS enantiomers have been investigated
as antibiotics in the treatment of Bcc lung infections.
In M. tuberculosis, the primary targets of DCS are D-alanyl-D-alanine synthetase
and D-alanine racemase, both necessary for viability. However, CS is a broad-
range inhibitor, reacting with many PLP-dependent enzymes in the cell. Since
this thesis focuses on the lipid A biosynthesis and aminoarabinose modification
pathways as drug targets, I chose to study in vitro CS inhibition with the only
PLP-dependent enzyme, ArnB, involved in these pathways.
3.1 CS activity against the Bcc
To investigate the potential of CS in treatment of Bcc infections, the in vitro
antimicrobial activity of CS towards Bcc species was tested. Minimal inhibitory
(MIC) and bactericidal (MBC) concentrations were determined for CS, and syn-
ergistic studies were performed with front-line antibiotics used in the current
treatment of Bcc infections.
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3.1.1 MIC
MICs of CS were determined for all strains of the Bcc reference panel [35, 38]. As
described for CHIR-090 in the previous chapter, MIC data was generated using
the internationally accepted BSAC methodology [184] for other Gram-negative
pathogens. The quality control strains P. aeruginosa ATCC27853, P. aeruginosa
ATCC10145, and E. coli ATCC25922 species were included, as recommended
by the guidelines. ISA plates contained two-fold dilutions of DCS (range 0-
1000 µg/ml) or LCS (range 0-128 µg/ml) and MICs were defined as the lowest
concentrations of CS where no visual growth could be observed.
LCS did not inhibit the growth of any of the strains tested in the tested concen-
tration range. All MICs of LCS are >128 µg/ml, including the control strains
P. aeruginosa and E. coli. However, in the same study LCS showed activity
against two Sphingomonas strains (results not shown), indicating that the ob-
served lack of growth inhibition by LCS was not caused by an experimental
error.
In contrast to that observed with LCS, the growth of all Bcc and control strains
was inhibited within the range of DCS concentrations tested. MICs of DCS
against the Bcc are shown in Table 3.1 and varied between 2 and 128 µg/ml.
Interestingly, with one exception, namely B. vietnamiensis FC441, DCS proved
to be more active against Bcc strains than P. aeruginosa strains. As previously
described for the LpxC inhibitor CHIR-090 [197], the individual strains within the
nine Bcc reference species displayed different susceptibility to DCS. The three epi-
demic B. cenocepacia ET12 lineage strains (J2315, K56-2 and BC-7) showed the
highest MICs. The MIC for B. cenocepacia SAL-1, the deep-rough K56-2 deriva-
tive [183], was similar to the parental strain, indicating that as for CHIR-090,
the LPS profile does not influence the susceptibility toward DCS. B. multivorans
249-2, derived from ATCC17616, displayed a higher MIC value than the parental
strain. This is in contrast to what was found for CHIR-090, where B. multivorans
73
Table 3.1: MIC values of D-cycloserine against the Bcc reference panel and control
strains.
Strain MIC (µg/ml) Strain MIC (µg/ml)
B. cepacia (I) B. dolosa (VI)
ATCC25416 32 AU0645 32
ATCC17759 32 CEP021 32
CEP509 64 E12 4
LMG17991 STM1441 16
B. multivorans (II) B. ambifaria (VII)
C5393 4 AMMD 8
LMG13010 8 ATCC53266 8






B. cenocepacia (III) B. anthina (VIII)
J2315 64 W92 4
BC7 64 C1765 4
K56-2 64 J2552 16








B. stabilis (IV) B. pyrrocinia (IX)
LMG14292 4 ATCC15958 4
C7322 16 ATCC39277 4
LMG14086 2 BC011 16
LMG18888 16 C1469 8
B. vietnamiensis (V) E. coli
PC259 64 ATCC25922 64
LMG16232 32 P. aeruginosa
FC441 128 ATCC27853 128
LMG10929 32 ATCC10145 128
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249-2 showed an extremely low MIC value (0.1 µg/ml) compared to the parental
strain (6.25 µg/ml). The three B. ambifaria strains were amongst the most sus-
ceptible Bcc strains with MICs of 4-8 µg/ml. B. stabilis strain LMG14086 showed
the lowest (2 µg/ml) MIC of all Bcc strains.
In a previous study, clinical (multiple drug-resistant) isolates of M. tuberculosis
and the type strain H37Rv showed MICs of DCS ranging from 25 to 75 µg/ml [198].
In my study, the MICs of DCS against the Bcc are in the same range or even
lower, suggesting that DCS might have a clinically useful activity against the Bcc.
3.1.2 Bactericidal and synergistic activity of DCS
To determine the bactericidal or bacteriostatic activity of DCS towards the Bcc,
a panel of relevant strains was assembled (Table 3.2). This panel consisted of six
strains of the two most clinically relevant species, B. multivorans and B. ceno-
cepacia, together with a P. aeruginosa and an E. coli control strain.
MICs for the eight strains tested were examined in IS broth containing two-fold
dilutions of DCS (range 0-500 µg/ml). After incubating the strains overnight with
DCS, the MIC was determined as the first concentration at which no turbidity or
visual growth could be observed. The MIC concentration and a two-fold higher
concentration was used as an inoculum to plate on non-antibiotic containing agar
plates and survival of the strains (confluent growth) was checked the following day.
The DCS concentration at which no survival was observed is given in Table 3.2
as the MBC.
The MICs in broth corresponded to the MICs found on agar plates. DCS was
found to be bactericidal towards the Bcc. All MBCs were within 1 dilution of
the respective MICs, except for B. cenocepacia K56-2 which had an MIC value
of 64 µg/ml but still showed confluent growth after incubation in 128 µg/ml
DCS. Interestingly, LiPuma and colleagues reported that the nanoemulsion NB-
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Table 3.2: MIC and MBC values (µg/ml) of DCS against a panel of clinically
relevant strains.
Strain Source/reference MIC MBC
E. coli
ATCC25922 ATCC 64 64
P. aeruginosa
ATCC10145 ATCC 128 128
B. multivorans
C5393 Vancouver CF clinic [185] 4 8
C1575 Glasgow Epidemic [60] 32 64
ATCC17616 Environmental strain [47] 16 32
B. cenocepacia
J2315 Edinburgh Epidemic [26] 64 128
K56-2 Toronto CF clinic [63] 64 >128
ATCC17765 Urinary tract infection [47] 16 32
401 showed MBCs typically within two-fold of the MIC value, but also reported
a single B. cenocepacia strain exception [194]. However, LiPuma et al did not
indicate which B. cenocepacia strain showed a different profile.
In the treatment of multiple drug-resistant Bcc infections, as well as other Gram-
negative infections, such as P. aeruginosa, antibiotics are usually not used as
single agents but rather in combination with other antibiotics. Therefore, I inves-
tigated the synergistic activity of DCS with seven front-line antibiotics presently
used to treat Bcc infections: minocycline, ceftazidime, tobramycin, meropenem,
chloramphenicol, trimethoprim, and ciprofloxacin. A panel of strains was assem-
bled, including three B. multivorans strains, three ET12 lineage B. cenocepacia
strains, one B. dolosa strain, and two control strains (P. aeruginosa and E. coli).
Synergistic activity was tested by a double disc diffusion assay. One filter disc
was impregnated with DCS and the other with one of the above-mentioned an-
tibiotics. The diameter and shape of the zones of inhibition were evaluated after
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overnight incubation. No clear change in size or shape of the inhibition zones
could be observed for all seven antibiotics when used alone or together with DCS
(results not shown). Hence, it was concluded that with the method used, DCS did
not act synergistically or antagonistically with any of these seven clinically-used
antibiotics. It should be noted that many methods of antibiotic synergy testing
against bacteria have been described but no reproducible guidelines for synergy
testing against the Bcc have been reported. It is known, however, that the re-
sults of synergy tests dependent on the method applied, the concentrations of
antibiotics used, and duration of drug exposure [199]. Therefore, the synergistic
or antagonistic mode of action of DCS with these antibiotics cannot be excluded.
3.2 ArnB: a possible intracellular DCS target
Encouraged by the antimicrobial activity studies of DCS against the Bcc, it was
decided to study DCS inhibition of the ArnB enzyme in vitro.
In a recent study by the Campopiano group and collaborators showed that in
contrast to S. typhimurium, the putative genes (including ArnB) involved in L-
Ara4N synthesis and LPS modification are essential for viability to B. cenocepacia
K56-2 [98]. Moreover, the lipid A structures described for different Bcc species
indicate that, in contrast to other Gram-negative bacteria, lipid A is always non-
stoichiometrically substituted with L-Ara4N [28]. When combined, those findings
suggest that the L-Ara4N biosynthetic pathway could be a rational target for
antibiotic therapy. Also, from those studies I learned that the Bcc has, in addition
to the broad range of intracellular DCS targets, a possible unique target, namely
ArnB.
Thomas Vargues, a former PhD student from the Campopiano group, recently
cloned, expressed, and purified ArnB of B. cenocepacia J2315 and performed
initial in vitro inhibition studies with CS [200]. In this section, the optimisation
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of his work and additional inhibition studies on the B. cenocepacia J2315 ArnB
enzyme are described.
3.2.1 Expression and purification of ArnB-His6
The expression plasmid pET22b ArnB J2315, expressing ArnB with a C-terminal
6 His tag, was kindly given by Thomas Vargues. Integrity of the plasmid was
proven by a restriction digest and by sequencing of the plasmid (results not
shown).
The method of ArnB-His6 purification was adapted from the method described
previously [200], with some modifications. For recombinant ArnB-His6 expres-
sion, E. coli BL21(DE3) competent cells, transformed with pET22b ArnB J2315,
were used. Expression was induced with 0.5 mM IPTG for 5 hours at 37 oC (Fig-
ure 3.2, Lane 3). ArnB-His6 was expressed as a soluble protein and purified
using IMAC nickel affinity (Figure 3.2, Lane 4) and size exclusion chromatogra-
phy (Figure 3.2, Lane 5). As judged by SDS-PAGE, ArnB-His6 was purified to
near homogeneity after these two chromatography steps. A yield of 15 mg of pure
recombinant ArnB-His6 protein was generally obtained from one litre of E. coli
BL21 (DE3) culture. Based on the elution profile of the size exclusion chro-
matography column, ArnB-His6 behaved as a monomeric protein (Figure 3.2),
in contrast to the homodimeric Salmonella ArnB [156]. Molecular weight of the
protein (theoretical mass = 43,252 Da) was confirmed by MALDI-TOF mass
spectometry (Appendix A.4).
Prior to further studies, ArnB-His6 was saturated with the PLP co-factor. The
purified enzyme was dialysed against an excess of PLP overnight after which the
un-bound PLP was removed using a PD10-column.
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Figure 3.2: ArnB purification profile. a) All consecutive expression and purifica-
tion steps were analysed by SDS-PAGE. Lane 1 and 6 show the molecular weight
marker, lane 2 = E. coli BL21 before induction, lane 3 = the cell free extract
after IPTG induction, lane 4 = the Ni-NTA chromatography elution fraction,
and lane 5 = fractions 13-15 of the S-200 size exclusion column. b) The elution
profile of ArnB-His6 running through the S-200 size exclusion column.
3.2.2 ArnB-His6 activity studies
As described in the introduction, ArnB is a transaminase that catalyses the amino
group transfer from glutamic acid to UDP-Ara4O, yielding UDP-L-Ara4N and
α-ketoglutarate [150]. The catalysed reaction consists of two half reactions (Fig-
ure 3.3). In the first half reaction, the amino group of L-glutamate is donated to
the active site of the protein. In the second half, the amino group is transferred
from the active site to the substrate UDP-Ara4O. Since the substrate, UDP-
Ara4O, is not (commercially) available, enzyme activity and inhibition studies
could only be performed on the first half reaction.
Enzyme assays could be carried out using UV-Vis spectroscopy. The holo-enzyme
(E-PLP) has absorption maxima of 415 nm and 328 nm (Figure 3.4), correspond-
ing to the ketoenamine and enolimine forms of E-PLP.
To test for activity of ArnB-His6, the natural amine donor, L-glutamate, was
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Figure 3.3: The two half reactions of ArnB. Adapted from [150].
Figure 3.4: Absorbance spectrum of ArnB-His6 in the E-PLP form.
added to the enzyme. After addition of L-glutamate, at 415 nm absorbance,
the peak of the internal aldimine was within seconds decreased to ∼30% and an
increase of a new peak with a λmax at 334 nm could be observed (Figure 3.5).
This increase in peak size of 334 nm can be assigned to the transfer of the amine
group to ArnB-His6, forming the E-PMP complex.
After completion of the enzymatic reaction with L-glutamate, regeneration of
the enzyme to its E-PLP state was attempted by dialysis in an excess of fresh
PLP overnight. The unbound PLP was removed before a new assay was carried
out. A scan was taken of the ”regenerated” enzyme before the addition of L-
glutamate and directly after the addition of L-glutamate. A good recovery of
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Figure 3.5: Absorbance spectra of ArnB-His6 activity. ArnB-His6 (14 µM) E-
PLP enzyme (solid line) and 1 minute after incubation with 500 µM L-glutamate
(dashed-dotted line).
the enzyme to E-PLP could be observed (Appendix A.5). However, even after
overnight dialysis, a significant amount of the enzyme remained in the E-PMP
form. The recovered enzyme was reacted again with L-glutamate in a the same
fashion as before dialysis and E-PLP was formed.
The above purification procedure and activity assay for ArnB-His6 worked well
when a potassium phosphate- or ammonium acetate buffer was used for all pu-
rification steps and assays. However, when the phosphate buffer was replaced by
Tris buffer (same pH) the elution profile of the size exclusion column was less
defined and the protein lost activity (results not shown). Since Tris has an amine
group it might be that the buffer reacts with the PLP co-factor in the active site
of the protein and thereby interferes with the activity assay.
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3.2.3 Cycloserine inhibition of ArnB-His6
Both CS enantiomers, LCS and DCS, have been described as inhibitors of a
wide range of PLP-dependent enzymes. Depending on the targeted enzyme and
conditions tested (e.g. pH of buffers) CS inhibition can be reversible or not. In-
hibition with CS has been described for several transaminases (e.g. D-amino acid
transaminase [201]), decarboxylases (e.g. dialkylglycine decarboxylase [202]), and
racemases (e.g. alanine racemase [203]). In contrast to most enzyme inhibitors
that typically form covalent interactions with the protein, CS binds covalently
to the PLP co-factor and the interaction with the enzyme itself is non-covalent.
Therefore, enzyme activity can be restored for many CS-inhibited enzymes (e.g.
D-amino acid transferases [201] and for bacterial serine palmitoyltransferase [204])
by dialysis against an excess of fresh PLP that can replace the CS-bound PLP
in the active site. However, the time required to restore activity by dialysis is
generally on a scale that is not of physiological relevance [205].
The ArnB of S. typhimurium has been shown to be inhibited by LCS enan-
tiomer [156]. When LCS was added to ArnB-His6, an instantaneous decrease of
the internal aldimine peak at 415 nm was observed and a new peak appeared
with a λmax at 328 nm. Additionally, a shoulder between 365 and 395 nm can be
observed (Figure 3.6). The UV-Vis spectra did not show any significant changes
after ∼10 minutes and the time of incubation (8 or 24 hours) did not influence
the spectra.
An analogous change in absorbance has been described for S. typhimurium ArnB
[156]. Ten minutes after the addition of LCS to the enzyme, when no further
change in absorbance spectra could be observed, L-glutamate was added to the
reaction mixture. This addition of L-glutamate did not cause changes in the
absorbance spectra, indicating that the enzyme was inhibited. However, it should
be noted that the peak that arises when ArnB-His6 reacts with LCS (328 nm)
lies only 6 nm away from the λmax of the E-PMP (334 nm) peak, which might
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Figure 3.6: Absorbance spectra of ArnB-His6 in the E-PLP form (solid line) and
10 minutes after addition of 1 mM LCS (dashed line).
make it difficult to observe any changes in the spectrum.
The absorbance spectrum of ArnB-His6 changed in the presence of DCS (Fig-
ure 3.7). However, the completion of the reaction took considerably longer for
DCS than for LCS, and the spectra of DCS and LCS when reacted with ArnB-
His6 differ greatly. When DCS is added, both E-PMP peaks at 415 and 328 nm
were reduced in size over time and a new peak appeared with a λmax of 372 nm.
After ∼20 minutes, the E-PMP peaks completely disappeared. However, when
L-glutamate was added at this point, some ArnB-His6 activity remained and rise
of the E-PLP peak at 334 nm could be observed (results not shown). After incu-
bating DCS with ArnB-His6 for over 30 minutes, a broad shoulder on the 372 nm
peak appeared (Figure 3.7) and the λmax was shifted to 360 nm. After ∼3 hours,
no significant change in the spectrum could be observed. When L-glutamate was
added after prior incubation with DCS, no change in the spectrum was observed,
indicating that ArnB-His6 was inhibited.
For alanine racemase, it has been reported that UV-Vis spectra for both CS
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Figure 3.7: Absorbance spectra for ArnB-His6 in the E-PLP (solid line) form, 20
minutes (blue dashed line) and 3 hours (red dashed line) after addition of 1 mM
DCS. After 3 hours of incubation with DCS, 500 µM L-glutamate was added and
a scan was taken after an additional 10 minutes (black dashed-dotted line).
enantiomers reacted with the enzyme are similar [203]. In contrast, for ArnB-
His6, both enantiomers show different absorbance profiles when incubated with
the enzyme and none of the peaks formed had the same λmax as the E-PMP
peak (Figure 3.8). This suggests that both enantiomers do not act as amine
donors but pursue different reaction pathways dependent upon CS chirality. A
difference in reaction pathway of LCS and DCS has been described for several
enzymes, including dialkylglycine decarboxylase [202] and bacterial serine palmi-
toyltransferase [204].
Several mechanisms of CS inhibition have been reported and seem to differ be-
tween enzymes. So far, it is not possible to predict the mechanism of inhibition
based on differences or similarities in the absorption spectra between enzymes.
The crystal structure of S. typhimurium ArnB with LCS in the active site showed
that LCS binds the co-factor by replacing the lysine-PLP aldimine bond by an
LCS-PLP amine bond (Figure 3.9). The LCS-PLP adduct showed that the LCS
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Figure 3.8: Absorbance spectra for ArnB-His6 in the E-PLP form (black), 10
minutes after addition of 500 µM L-glutamate (green), 1 mM DCS (red), or
1 mM LCS (blue).
ring stays in its cyclic form [156], as described in the case of alanine racemace CS
inhibition [203]. Recently, it has been published for the bacterial serine palmi-
toyltransferase, that LCS inhibition of the enzyme shows a similar UV-absorption
profile as published for S. typhimurium ArnB. However, in that study, PLP-LCS
or PLP-DCS adducts could not be identified by mass spectrometry or enzyme
crystallography where the CS ring was still in its cyclic form. A new CS inhibi-
tion mechanism involving the opening of the ring followed by decarboxylation of
the opened ring was proposed [204]. Similar mechanisms involving the opening
of the ring have been proposed in other previous studies [206]. Furthermore, in
a study on serine palmitoyltransferase, it was found that both CS enantiomers
show different absorption spectra when inhibiting the enzyme, but the same PLP-
adduct was isolated from enzymes inhibited with both LCS and DCS [204]. Both
UV-absorption profiles presented here for CS-inhibited ArnB-His6 are similar to
the absorption profiles published for the serine palmitoyltransferase enzyme.
To test for the reversibility of CS inhibition, the inhibited protein was dialysed
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Figure 3.9: Proposed inhibition mechanism of LCS of S.typhimurium ArnB.
overnight in an excess of fresh PLP. The unbound co-factor was then removed
using a PD-10 column. A UV-Vis spectrum of the enzyme was taken after dialy-
sis and activity of the protein was tested by adding L-glutamate. For both LCS-
and DCS-inhibited proteins, activity could be partly recovered by dialysis (Ap-
pendix A.7), however, a significant amount of ArnB-His6 still has LCS or DCS
bound after dialysis.
To gain further insight into the mechanism of inhibition of both enantiomers,
several methods were attempted to isolate the PLP-DCS and PLP-LCS adducts
for mass spectrometry analysis. We tried to denature the enzyme, leaving the
adduct in solution by: 1) adding 8 M urea (with or without boiling), 2) by
increasing the pH from 7.5 to 12 [206], and 3) by filtering the protein, using a
3 kD spin filter. Unfortunately, none of those attempts was successful. Though
CS is non-covalently bound into the active site, the combined affinity of the PLP-
CS may be very high, as described for other non-covalent inhibitors [205].
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3.2.4 Inhibition studies with β-chloroalanine and propar-
gylglycine
PLP-dependent enzymes have been extensively studied and many inhibitors of
this class of enzymes have been described. Therefore, based on previous ArnB
studies in S. typhimurium ArnB [156], I decided to test for the inhibitory activity
of other well known PLP-dependent enzyme inhibitors. Two inhibitors, gabac-
uline and ibotenic acid, were tested in previous studies for inhibition of ArnB-
His6 [200], but neither of those showed reactivity towards ArnB-His6. Thus,
ArnB-His6 reactivity with β-chloro-D-alanine (βCDA) and L-propargylglycine
(L-PPG) was tested.
Inhibition studies with β-chloro-D-alanine
A powerful synergistic activity (MIC of DCS was reduced from 50 to 2.5 µg/ml)
of DCS and βCDA against M. tuberculosis has been reported [207]. Therefore it
was decided to test if βCDA could inhibit ArnB-His6.
Similar to CS, βCDA is an alanine analogue that can inhibit alanine racemase and
a range of D- and L-amino transferases. However, a difference between CS and
βCDA is that inhibition with βCDA is irreversible due to the fact that the PLP-
cofactor remains covalently bound to the enzyme after inhibition (Figure 3.10).
βCDA binds to the active site where it can displace the lysine-PLP aldimine
bond by a βCDA-PLP aldimine bond. Formation of the quinonoid intermediate
takes place by deprotonation in the α-position of βCDA, followed by the repro-
tonation of the quinonoid and release of HCl to form an aminoacrylate aldimine
species. The lysine residue displaces the aminoacrylate-PLP amine bond and
aminoacrylate is released. The free aminoacrylate can nucleophilically attack the
co-factor to form a stable covalent bond, thereby inhibiting the enzyme, or it
diffuses out of the active site where it is spontaneously degraded to ammonia and
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Figure 3.10: Mechanism of inhibition of PLP-dependent enzymes by βCDA.
Adapted from [205].
pyruvate [205, 208].
ArnB-His6 (14 µM final concentration) was incubated with different concentra-
tions of βCDA (500 µM, 1 mM, and 2 mM) for one minute and UV-Vis spectra
were generated (Figure 3.11). An increase in peak size could be observed with a
λmax of 326 nm. However, in contrast to the activity and inhibition assays shown
for L-glutamate, DCS, and LCS, the 415 nm internal aldimine peak did not sig-
nificantly decrease. This suggests that βCDA is binding to ArnB-His6, and that
the enzyme uses βCDA as a substrate, thereby regenerating the enzyme into an
active form, a phenomenon that has been reported for several other aminotrans-
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ferases [208, 209]. As described above, when βCDA is used as a substrate by
aminotransferases, pyruvate and ammonia are released.
Figure 3.11: Absorbance spectra for ArnB in the E-PLP (solid line) form and 1
minute after addition of 500 µM (dotted line), 1 mM (dashed line), and 2 mM
(dashed-dotted line) βCDA.
To confirm that ArnB-His6 uses βCDA as a substrate and pyruvate is indeed
released, a coupled assay with lactate dehydrogenase (LDH) was performed (Fig-
ure 3.12a). The assay was activated by the addition of βCDA to ArnB-His6,
and the reaction was followed by UV-Vis (Figure 3.11). After completion of the
reaction, NADH was added to the reaction mixture, thereby increasing the ab-
sorbance at 340 nm. A new reaction was then initiated by addition of LDH to
the reaction mixture. LDH uses pyruvate as a substrate to form L-lactate, util-
ising the co-factor NADH to NAD+. The decrease of absorbance at 340 nm was
followed over time by UV-Vis (Figure 3.12b). As controls, NADH and LDH were
added to a reaction mixture that only contained ArnB-His or βCDA.
Figure 3.12b clearly shows that pyruvate is released when ArnB-His6 is incubated
with βCDA, and therefore it was concluded that βCDA acts as a substrate and
not as an effective inhibitor of ArnB-His6.
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(a) (b)
Figure 3.12: a) ArnB-His6-βCDA activity assay. ArnB-His6 uses βCDA as a
substrate and pyruvate is released. LDH uses pyruvate as a substrate to form
L-lactate, utilising the co-factor NADH to NAD+. b) Decay of absorbance at
340 nm after the addition of NADH and LDH to the ArnB-His6- βCDA reaction
mixture (solid line), to ArnB-His6 (dashed line) and to βCDA (dotted line).
Inhibition studies with L-propargylglycine
L-PPG is an irreversible inhibitor of PLP-dependent enzymes. Unlike CS and
βCDA, L-PPG forms a covalent bond with one of the amino acids in in the active
site of the protein (Figure 3.13). Similar to the natural substrate of the enzymes,
L-PPG binds in the active site where it can displace the lysine-PLP aldimine bond
by a L-PPG-PLP aldimine bond. Formation of the quinonoid intermediate takes
place by deprotonation in the α-position of L-PPG, followed by the reprotonation
of the quinonoid species to generate a ketimine. In this case the ketimine is not
hydrolysed, but the acetylene moiety of L-PPG isomerises to form an allene. This
highly reactive allene is nucleophilically attacked by a residue in the active site
and a stable covalent bond is created [205, 208].
When 500 µM L-PPG was added to 14 µM ArnB-His6, it was observed that ArnB-
His6 reacted with L-PPG after ∼10 and that a new peak developed at 324 nm.
However, it took ∼16-24 hours till the reaction was completed (Figure 3.14).
The data suggests that ArnB-His6 is reacting with L-PPG, but that the reaction is
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Figure 3.13: Mechanism of inhibition of PLP-dependent enzymes by L-PPG.
Adapted from [205].
very slow. Further studies were not performed due to severe solubility problems,
which arose when a higher concentration of L-PPG was added to the enzyme.
After completion of the reaction with 500 µM L-PPG (∼16-24 hours at 25 oC),
the protein precipitated when L-glutamate was added to the reaction mixture. In
addition, it was not possible to dialyse the L-PPG bound ArnB-His6 in fresh PLP-
buffer since under these conditions the protein was also sensitive to precipitation.
3.3 Conclusion
Bcc species have the potential to cause rapidly lethal ”Cepacia syndrome” in CF
individuals and treatment of such infections is virtually impossible. Most antimi-
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Figure 3.14: Absorbance spectra for ArnB in the E-PLP (solid line) form, 10 min-
utes (dashed-dotted line), and 24 hours (dashed line) after addition of L-PPG.
crobial research has focused on finding natural products with novel antimicrobial
activity, modification of existing drugs, or on the chemical design of new drugs.
In this chapter, I followed a different path, by investigating the potential role
that the ”old” antibiotic Seromycin (DCS) might play in the treatment of Bcc
infections.
Interestingly, we demonstrated that DCS could inhibit growth of all strains in the
Bcc reference panel, and acted bactericidally against five out of six Bcc species
tested; this included the highly virulent strains B. cenocepacia J2315 and B. mul-
tivorans C1575. DCS is a drug that is already in use in the treatment of multiple
drug-resistant M. tuberculosis and the Bcc strains tested showed MICs in a similar
range or even lower than previously published for clinical isolates of M. tubercu-
losis. These results indicate that, in vitro, Bcc strains are at least as susceptible
towards DCS as M. tuberculosis strains, and that DCS might be of clinical use in
the treatment of Bcc infections. The site of infection of the Bcc in the lungs is
similar to the site of infection of M. tuberculosis. Also, both species can survive
intracellularly, which implies that DCS is capable or reaching the Bcc species in
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vivo at bactericidal concentrations.
Although it is ’early days,’ as the following statement shows, there is certainly a
clinical need for an effective therapy against Bcc infections.
”Seromycin? Not heard of it, but willing to try anything for
Cepacia syndrome.” Dr. Alistair Innes, chest physician at Western
General Hospital, Edinburgh. Personal communication 2010.
These results suggest that DCS (Seromycin) could be considered as an additional
antibiotic in the treatment of lethal Bcc infectious of the CF lung. Conversely,
care should be taken with the severe side effects, such as hallucination, confusion,
and depression, reported for DCS in the treatment of tuberculosis. One option
would be that, for the present, and as for M. tuberculosis infections, DCS should
only be considered as a second line drug. Future research could then focus on
efficient delivery of the drug, possibly as an aerosol, to limit the toxic side effects.
This section of the thesis has demonstrated that the L-Ara4N biosynthesis path-
way might be a reasonable target for antimicrobial therapy against the Bcc. ArnB
uses PLP as a co-factor. Therefore, ArnB of B. cenocepacia J2315 was chosen as
the enzyme to study the in vitro CS inhibition and the potential of antibiotics
targeting the L-Ara4N biosynthesis pathway. It was shown that ArnB-His6 activ-
ity could be inhibited by both LCS and DCS and the differences in the inhibition
spectra were highlighted. LCS also showed a similar inhibition profile to that
described for S. typhimurium ArnB [156]. Though both enantiomers showed re-
activity towards ArnB-His6, only DCS showed antimicrobial activity against the
Bcc. At present, a conclusive interpretation of those results cannot be provided,
but the data could be explored by further research. In addition, as isolation of the
PLP-LCS or PLP-DCS adducts was not achieved, the mechanism of inhibition of
both CS enantiomers remains to be clarified.
Unlike other enzyme inhibitors that form covalent interactions with the protein,
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both CS enantiomers form a stable covalent interaction with the PLP co-factor,
but the interaction with the enzyme is non-covalent. Therefore, enzyme activity
can be restored for many CS inhibited enzymes by dialysis against an excess of
PLP [204, 201], including ArnB-His6. However, the time it takes to restore activ-
ity by dialysis is generally on a scale that is not of physiological relevance [205].
Though ArnB-His6 is inhibited in vitro by DCS, I do not have any evidence that
DCS targets ArnB intracellularly if used against the Bcc. If DCS targets ArnB
intracellularly I would expect that when the Bcc is grown in the presence of DCS,
to observe accumulation of membranous material. Interestingly, this phenotype
has recently been described for strain B. cenocepacia XAO12, a conditional ArnB
mutant of B. cenocepacia K56-2 [98]. This hypothesis is being further investi-
gated by the group of Prof. Miguel Valvano (Infectious Diseases Research Group,
University of Western Ontario), who have the expertise and the resources for this
research.
Of the two other PLP-dependent enzyme inhibitors tested, L-PPG might be a
slow inhibitor of ArnB-His6 and could be further explored; however solubility
issues might hamper this research. For the well-known PLP-dependent enzyme
inhibitor βCDA, I proved that it cannot inhibit ArnB-His6, but that ArnB-His6
uses βCDA as a substrate.
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Chapter 4
L-Ara4N Specificity of Lipid A
Transport: LptA & LptB
LPS isolated for the studies described in this chapter was also used for pub-
lished collaborative work:
Ganesh V., Bodewits K., Bartholdson SJ., Natale D., Campopiano D. J., Mareque-
Rivas J. C. Effective binding and sensing of lipopolysaccharide: combining complemen-
tary pattern recognition receptors. Angew. Chem. Int. Ed. 2009, 48, 356-60
In the previous chapter, I explored ArnB as a drug target and showed that ArnB
can be inhibited by some PLP-dependent enzyme inhibitors. Also, it is known
that the ORFs in the putative L-Ara4N operon are essential for B. cenocepacia
survival [98]. The question remains, however, why L-Ara4N is necessary for
viability in B. cenocepacia. A possible explanation is that non-stoichometrically
attached L-Ara4N is necessary for membrane stability and that loss of it cannot
be compensated for in a different manner. Secondly, it could be that the necessity
of L-Ara4N depends on the growth conditions of B. cenocepacia, and that it is
essential under laboratory conditions tested, but not in all environmental niches.
A third explanation might be that L-Ara4N is essential for lipid A transport and
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that L-Ara4N-deficient mutants fail to transport lipid A. This last hypothesis
seems to be most likely since it is consistent with the accumulation of membranous
material inside the cell observed in the conditional lethal ArnB and ArnT mutant
strains [98]. It was previously noted that the phenotype of the B. cenocepacia
ArnB and ArnT mutant strains was very similar to the phenotype observed
for E. coli mutant with defects in the OM LptD/LptE transport complex [98,
174]. I observed that the phenotype of B. cenocepacia ArnB and ArnT mutant
strains was strikingly similar to a conditional lethal E. coli LptA/LptB mutant
(Figure 4.1) [165].
Figure 4.1: Electron microscopy images of B. cenocepacia K56-2 (A) wild type
strain and a conditional lethal ArnT mutant knock-out strain [98], and (B) E. coli
wild type and the conditional lethal LptA/LptB mutant [165].
In this chapter, the LptA and LptB homologs of B. cenocepacia J2315 are char-
acterised in vitro to explore if either of these proteins are specific for L-Ara4N-
modified lipid A. Moreover, LptB of E. coli has recently received renewed interest
as a target for new antimicrobial agents. Therefore, I tested two kinase inhibitors
for their ability to inhibit B. cenocepacia LptB.
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4.1 LptA (LPS transport protein A)
LptA is a soluble periplasmic protein that has been shown to bind lipid A and
facilitates lipid A transport through the periplasm. LptA from E. coli has been
characterised [171] and the x-ray crystal structure has been solved [178]. Char-
acterisation of the B. cenocepacia LptA homolog has not yet been attempted.
Genome analysis indicated that the putative B. cenocepacia LptA (BCAL0815)
and LptB (BCAL0814) genes are located in the same operon (Figure 4.2), as
found in E. coli [165]. LptA lies upstream of LptB and the genes overlap by 4 bp.
As in E. coli, the genes share an operon with kdsD and kdsC, both encoding
proteins involved in the biosynthesis of Kdo sugars (found in the inner core of
lipid A). In contrast to E. coli, LptC (YrbK ) and YrbG (unknown function) are
not found in the B. cenocepacia operon. Moreover, upstream of LptA a hypo-
thetical gene of unknown function is located, which to date does not have any
homologs in non-Burkholderia species.
Figure 4.2: Genetic organization of the (putative) operon where LptA and LptB
are located: (a) in B. cenocepacia J2315 (www.burkholderia.com); and (b) in
E. coli [165].
The B. cenocepacia LptA sequence is 24% identical to E. coli LptA (Appendix
A.10). Like the E. coli LptA protein, LptABCAL0815 has a putative N-terminal
signal sequence of 46 bp facilitating the transport of the protein across the IM to
the periplasm.
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4.1.1 Cloning, expression, and purification of LptA-His6
In order to characterise the B. cenocepacia J2315 LptA protein, LptA was ampli-
fied from genomic DNA and cloned into the IPTG-inducible expression plasmid
pET22b, giving pET22b LptA J2315. To aid purification, a C-terminal 6 His tag
was introduced, as previously described for the purification of E. coli LptA. The
recombinant LptA-His6 was exressed in E. coli HMS174 (DE3) cells transformed
with the pET22b LptA J2315 plasmid. Expression of LptA-His6 was obtained
after an hour of induction. A longer induction time was avoided to reduce cell
lysis. LptA-His6 was solublised and purified using IMAC nickel affinity and size
Figure 4.3: LptA-His6 purification profile. a) All consecutive expression and pu-
rification steps were analysed by SDS-PAGE. Lane 1 = molecular weight marker,
lane 2 = E. coli HMS174 after induction, lane 3 = the cell free extract, lane 4 =
the Ni-NTA chromatography elution fraction, and lane 5 = fractions 12-15 of the
S-300 size exclusion column. b) The elution profile of LptA-His6 purified using a
S-300 size exclusion column and the Western Blot analysis after purification.
exclusion chromatography (Figure 4.3). The protein was purified to near ho-
mogeneity as judged by SDS-PAGE and its identity was verified by Western
Blot with a anti-polyhistidine monoclonal antibody. Size exclusion chromatog-
raphy showed that LptA-His6 behaved as a mixture of tetrameric and octomeric
proteins. The oligomerisation status of LptA-His6 differs from E. coli LptA,
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which has been showing to be a monomeric protein [171]. The molecular weight
of purified LptA-His6 was confirmed by MALDI-TOF mass spectrometry (Ap-
pendix A.9), and showed that the 46 amino acid long signal peptide (M1-A46)
was cleaved off (predicted MW= 20.4 kD, Appendix A.8). Interestingly, by SDS-
PAGE analysis of the purified LptA-His6, the presence of three protein species of
different molecular weight was observed. However, MALDI-TOF mass spectrom-
etry of the same sample showed only one molecular ion. A similar observation
has been described for E. coli LptA, where two bands are seen by SDS-PAGE
analysis. It was hypothesised that this is caused by conformational differences
causing altered electrophoretic migration characteristics of part of the purified
protein [171].
4.1.2 LptA-His6 LPS binding assay
To confirm that the B. cenocepacia LptA-His6 homolog is able to bind LPS and
to explore its specificity a LptA-His6-LPS binding assay was carried out. The
method used was adapted from the published E. coli LptA-LPS binding assay
[171]. Firstly, I chose to test the ability of LptA-His6 to bind L-Ara4N modified
deep-rough LPS. Therefore, LPS was isolated from B. cenocepacia SAL-1, using
the hot phenol-water method (Figure 4.4). Commercially available Kdo2-lipid A
(unmodified) of E. coli was used as a control. As judged by gel-electrophoresis,
discussed below, the isolation of SAL-1 LPS was successful.1
Purified LptA-His6 was incubated with Kdo2-lipid A (unmodified) or B. ceno-
cepacia SAL-1 LPS to allow binding of the protein to the putative ligands. The
protein was re-purified from the mixture using IMAC nickel affinity chromatog-
raphy. Then, the protein and ligands were analysed by gel-electrophoresis and
silver-staining to see whether the two different LPS’s would co-elute with the
1This LPS was also used for a collaborative study of which the publication can be found
attached to this thesis [210].
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Figure 4.4: LPS isolated from B. cenocepacia SAL-1 (a) and E. coli Kdo2-lipid A
(b) analysed by gel-electrophoresis followed by silver-staining. 1 = 10 µL of a
1 mg/ml solution; 2 = 10 µL of a 0.1 mg/ml solution.
protein (Figure 4.5). In these studies, a control was included where the protein
was incubated with LPS-free water.
Figure 4.5: (a) E. coli Kdo2-lipid A and (b) B. cenocepacia SAL-1 LPS binding
by LptA-His6. LPS and LptA-His6 was examined by SDS-PAGE followed by
silver-staining. FT = flow-through; W = washed (5 times); E = elutions. (c)
Control without LPS.
As shown in Figure 4.5, both types of LPS tested co-eluted with the protein,
indicating that both can bind to LptA-His6. Therefore, I concluded that B. ceno-
cepacia LptA can bind unmodified and modified LPS and is not L-Ara4N-specific.
Since I only tested Kdo2-lipid A and deep-rough LPS, it was decided to test if
LptA-His6 can bind rough- and smooth LPS as well. Smooth LPS was isolated
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from E. coli AY103 [152], an ArnT knock-out strain (kindly given by Prof. C. R.
H. Raetz, Duke University). This LPS was isolated using a published tri-reagent
method [211]. As shown in Figure 4.6, the smooth LPS displays the typical
ladder-like profile when analysed by SDS-PAGE. The LptA-His6-LPS binding
assay was repeated with this smooth LPS and I could observe that the LPS
co-elutes with LptA-His6. However, instead of the ladder-like profile a typical
deep-rough LPS profile was observed in the elution fraction. This could indicate
that LPS containing the O-antigen region does not bind to LptA-His6. However,
this phenomenon was not explored further and a conclusive answer cannot be
drawn.
A previous PhD student in the Campopiano group, Josephin Bartholdson, iso-
lated deep-rough LPS from B. cenocepacia J2315, using the hot phenol-water
method [212]. Therefore, it was decided to use this LPS to explore if LptA-His6
can bind this type of LPS. As shown in Figure 4.6, LptA-His6 can bind rough
LPS and the typical two-banded pattern of B. cenocepacia J2315 co-elutes with
the protein.
Figure 4.6: E. coli AY103 smooth LPS (a) and B. cenocepacia J2315 rough LPS
(b) binding by LptA-His6. LPS and LptA-His6 was examined by SDS-PAGE
followed by silver-staining. FT = flow-through; W = washed (5 times); E =
elutions.
The LptA-His6-LPS binding assays were all carried out directly after purifica-
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tion of the protein, which was necessary due to the instability of the protein.
LptA-His6 degrades within hours after purification. Repeatedly, a ∼4 kDa frag-
ment would cleave off the C-terminus, leading to precipitation of the protein.
The cleavage after ∼4 kDa was confirmed with MALDI-TOF analysis (Appendix
A.9). This degradation suggested that a protease was co-purified with LptA-His6.
However, several attempts to add additional protease inhibitors to the purifica-
tion buffers, such as phenylmethylsulfonyl fluoride (PMSF), EDTA, leupeptin, or
tosyl phenylalanyl chloromethyl ketone (TPCK), failed to stabilise the protein.
EDTA was the only inhibitor tested which could slow down the decomposition
but not completely prevent it. The fact that this decrease in decomposition was
effected by a complexing ligand hints at the presence of a metalloproteinase. Sev-
eral attempts to explore the binding affinity of ligand and protein in more detail,
by isothermal titration calorimetry (ITC) and dynamic light scattering (DLS),
failed due to this protein instability (data not shown).
4.2 LptB (LPS transport protein B)
LptB is a soluble cytoplasmic ATP-ase that forms a complex with LptC, LptF,
and LptG, and most likely delivers energy for the extraction of lipid A molecules
out of the phospholipid-bilayer of the IM. To date, no structural information
is available on the LptB from any organism. However, previous studies have
yielded kinetic characterisation of the E. coli isoform [168, 169]. Herein, I show
the characterisation of the B. cenocepacia J2315 LptB homolog in vitro.
4.2.1 Cloning, expression, and purification of LptB-His6
The LptB homologous gene (BCAL0814) was amplified from genomic B. ceno-
cepacia J2315 DNA. Then I constructed a plasmid able to express a C-terminal
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Figure 4.7: LptB-His6 purification profile. a) All consecutive expression and
purification steps were analysed by SDS-PAGE. Lane 1 and 8 = molecular weight
marker, lane 2 = E. coli BL21 before induction, lane 3 = after induction, lane 4 =
the cell free extract, lane 5 = the Ni-NTA chromatography elution fraction, lane 6
= fraction 9 of the S-75 size exclusion column, and lane 7 = fractions 11-13 of
the S-75 size exclusion column. b) The elution profile of LptB-His6 purified with
a S-75 size exclusion column and the Western Blot analysis after purification.
6 His tagged version of LptB under the control of the IPTG-inducible pro-
moter, pET22b LptB J2315. The recombinant LptB-His6 was exressed in E. coli
BL21 (DE3) cells transformed with the pET22b LptB J2315 plasmid.
The purification condition of the E. coli LptB-His6 isoform were published re-
cently [169], and I adopted the same strategy with some modifications to purify
B. cenocepacia LptB-His6. Though LptB-His6 does not have any membrane-
spanning domains, it is known to be associated to the IM. Therefore, it was
necessary to solubilise LptB-His6 by adding glycerol and DTT to the purification
buffers. Then, LptB-His6 was purified to near homogeneity using IMAC nickel
affinity and size exclusion chromatography (Figure 4.7). The identity of the pu-
rified protein was confirmed by Western Blot. The yield obtained was typically
∼8 mg of pure recombinant LptB-His6 per litre of induced E. coli BL21 (DE3)
cells. Judging from the elution profile of the size exclusion chromatography col-
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umn, LptB-His6 was purified as a mixture of monomeric and dimeric protein.
(Figure 4.7). The monomer molecular weight (predicted MW = 28.2 kDa) of the
protein was confirmed by MALDI-TOF mass spectometry (Appendix A.12).
The two peaks from the size exclusion chromatograhy column were assayed inde-
pendently and showed identical activity (results not shown).
4.2.2 Kinetic analysis of LptB-His6
To measure LptB-His6 activity, a similar assay was used as described for the
E. coli homolog [169]. An assay was used in which the production of ADP
by LptB-His6 is continuously detected using a pyruvate kinase (PK)- lactate
dehydrogenase (LDH) assay (Figure 4.8). Reactions were monitored by measuring
the decrease in NADH concentration in the reaction mixture over time at the
analytical wavelength of 340 nm.
Figure 4.8: LptB activity assay. LptB hydrolysis ATP to ADP and free phos-
phate. PK catalyses the transfer of a phosphate group from PEP to ADP, regen-
erating ATP and pyruvate. LD uses pyruvate as a substrate to form L-lactate,
utilising the co-factor NADH to NAD+. NADH absorbs UV light at a wavelength
of 340 nm. The decrease in NADH absorbance is proportional to the amount of
ATP hydrolysed.
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The assay was performed with variable concentrations of substrate and data was
plotted using the Michaelis-Menten equations (Figure 4.9). The initial reaction
rate was calculated by measuring the decrease in absorbance at 340 nm. The
molar extinction coefficient of NADH at 340 nm is 6220 M−1 cm−1. The data
was processed using SigmaPlot software and the Vmax, KM and Hill coefficient
were obtained from the graph. The kinetic parameter kcat was calculated from
the values obtained from the graph. The kcat value was found to be 5.71 min
−1.
The KM was found to be 0.88 mM, with a Hill coefficient of 1.6. A Hill coefficient
of >1 indicates that a cooperative reaction takes place, indicating that LptB acts
as a dimer. Our values are comparable to the kinetic parameters found for the
E. coli LptB of which the kcat is 6.2 min
−1 and the KM is 0.56 mM with a Hill
coefficient of 1.5 [169].
Figure 4.9: Kinetic analysis of LptB-His6. Michaelis-Menten representation, gen-
erated with SigmaPlot software.
Some ATP-ases can be activated or inhibited by their substrate. I explored,
whether the presence of LPS had an effect on LptB-His6 activity and if LptB-
His6 showed a specificity towards L-Ara4N modified LPS. Therefore I measured
the activity of LptB-His6 in the presence of variable concentrations of LPS. The
LPS’s tested included commercially available E. coli Kdo2-lipid A (unmodified),
deep-rough LPS isolated from B. cenocepacia SAL-1 (L-Ara4N-modified), rough
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LPS isolated from B. cenocepacia J2315, and smooth LPS isolated from E. coli
AY103. It was found that the presence of LPS in all concentrations tested did
not have any effect on the activity of LptB-His6 (data not shown). Previously, it
has been shown that the presence of Kdo2-lipid A also did not affect the activity
of E. coli LptB [168].
In the same study, it was shown that E. coli LptB could be inhibited with ortho-
vanadate (VO4), a well-known inhibitor of a number of ATP-ases. Furthermore,
during a high-throughput inhibition study of two commercially available kinase
inhibitor libraries, two compounds were found to inhibit E. coli LptB [169]. I
decided to test inhibition by orthovanadate and one of the inhibitors (inhibitor 2)
found during the high-throughput study (Chapter 1, Figure 1.17) of B. cenocepa-
cia LptB-His6. During my studies I could not observe any inhibition of LptB-His6
by either VO4 or inhibitor 2, not even after pre-incubation with the enzyme for
∼2 hours. It should be noted that the highest concentrations of inhibitor tested
were 22 µM for inhibitor 2 and 8 mM for orthovanadate. It was impossible to
increase the concentrations of the inhibitors in my assay since as with NADH
both inhibitors absorb at 340 nm. However, at the concentrations I tested E. coli
LptB was clearly inhibited [168, 169] and the B. cenocepacia enzyme was not.
4.3 Conclusion
In this chapter, I have tried to explain why L-Ara4N is necessary for viability
in B. cenocepacia, but not in other gram-negative bacteria, such as E. coli and
S. typhimurium. To answer this question, I characterised two proteins in vitro
involved in lipid A transport in B. cenocepacia, namely LptA and LptB. These
proteins were picked as targets since I observed a striking similarity in phenotype
between B. cenocepacia ArnB and ArnT conditional lethal mutant strains [98]
and the conditional lethal E. coli LptA/LptB mutant [165]. Therefore, it could
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be hypothesised that either LptA or LptB might show specificity to L-Ara4N-
modified LPS.
Both proteins were successfully cloned, expressed, and purified. The previously
putative B. cenocepacia LptA homolog did bind LPS in vitro as expected. How-
ever, this LptA was able to bind all types of LPS offered, like the E. coli isomer,
and was not specific for L-Ara4N-modified LPS.
The LptB homolog of B. cenocepacia showed ATP-ase activity in vitro and the
kinetic parameters that were found are in a similar range as the values described
in a very recent analysis of E. coli LptB. It was attempted to inhibit B. ceno-
cepacia LptB with two inhibitors that were shown to be active against E. coli
LptB, but in both cases no inhibition could be observed. This suggests that there
are differences in structure between the E. coli and B. cenocepacia LptB enzyme,
and that E. coli LptB inhibitors are not necessarily likely to be active against
B. cenocepacia. As with the E. coli LptB, the presence of any LPS (L-Ara4N-
modified or not) in the reaction mixture, had no influence on the activity of LptB.
Therefore, I concluded that LptA and LptB are not L-Ara4N-specific.
To my knowledge, this was the first study on B. cenocepacia proteins involved in
lipid A transport. However, the question still remains, why L-Ara4N is necessary
for viability. Future research could focus on the other proteins involved in lipid A




Burkholderia cepacia complex (Bcc) consists of a group of closely related Burkholde-
ria species that are opportunistic pathogens in patients with cystic fibrosis (CF) [12,
16, 17]. Though the risk of infection by Bcc species is relatively low, it is of great
concern with regard to CF patients. This because of four reasons: 1) infection
by Bcc leads, in approximately 20% of individuals, to Cepacia syndrome, a syn-
drome which in most cases is lethal [25]; 2) Bcc infections can be transmissible
from one patient to another [12] and have caused several epidemic outbreaks in
history [26, 27]; 3) successful treatment of Bcc infections is problematic due to
the inherent resistance of Bcc species to most classes of antibiotics; 4) Bcc in-
fection makes it necessary to segregate infected individuals from the rest of the
CF population, which has a great impact on the psychological well-being of the
patient [28].
Most Bcc species produce a wide variety of virulence factors that might cause
Cepacia syndrome, but none of these factors has been established as the main
causative agent [12]. The virulence factor I focused on during these studies was
LPS, which can, beside stimulating an immune response directly, be responsible
for the high resistance of Bcc species against polycationic compounds. Lipid A
(also known as endotoxin) is the hydrophobic anchor of lipopolysaccaride (LPS)
108
and is the bio-active component of LPS. The lipid A structure and composition of
Bcc members is distinct from the lipid A of other Gram-negative bacteria investi-
gated today. One of several unique characteristics of the lipid A of the Bcc, is the
permanent attachment of 4-amino-4-deoxy-L-arabinose (L-Ara4N) to the lipid A
molecule [28]. Also, the genes involved in L-Ara4N biosynthesis are necessary
for viability in B. cenocepacia [98]. In this thesis I presented research on lipid A
biosynthesis, modification, and transport in the Bcc and highlighted promising
antimicrobial targets.
Enzymes involved in the lipid A biosynthesis pathway, in particular LpxC, have
been recognised as attractive targets for new agents designed to treat infections
caused by Gram-negative bacteria [128]. The most potent inhibitor published
so far, which is capable of inhibiting growth of several Gram-negative species, is
the synthetic antibiotic CHIR-090. CHIR-090 showed good antimicrobial activ-
ity against several Gram-negative bacteria, such as E. coli and P. aeruginosa.
CHIR-090 is a slow, tight binding inhibitor of LpxC [144, 146], the enzyme
the catalyses the first irreversible step of the lipid A biosynthesis pathway. I
explored the potential of antibiotics targeting lipid A biosynthesis to treat Bcc
infections by investigating the activity of CHIR-090 against the Bcc. I showed
that CHIR-090 can inhibit growth of some Bcc species, including one of the most
prevalent Bcc species, B. multivorans. MICs were determined for eight B. mul-
tivorans strains and were found to be strain-dependent and ranged from 0.1 to
>100 µg/ml. Despite the close taxonomic relationship of the Bcc, individual iso-
lates displayed a remarkable difference in the sensitivity to CHIR-090 even within
a single species.The species- and strain-specific sensitivity towards CHIR-090 was
further explored and a strong correlation was found between the presence of a
unique open reading frame, named LpxC2, and the occurrence of resistance. I
showed that new drugs targeting this pathway have a potential to treat Bcc in-
fections. However, this potential is likely to be species- and strain-dependent. To
the best of my knowledge, this CHIR-090 study is the first to report an agent
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against Burkholderia targeted at the LPS biosynthetic pathway.
To address the problem of multiple drug-resistance of the Bcc, I explored the
potential and novel use of the ”old” antibiotic, cycloserine (CS), to treat Bcc in-
fections. CS is a pyridoxal 5′-phosphate (PLP)-dependent enzyme inhibitor that
binds to the PLP co-factor in the active site. CS is used as a second line of defense
against M. tuberculosis. Antimicrobial activity assays against the Bcc were per-
formed with both CS enantiomers, L-cycolserine (LCS) and D-cycloserine (DCS).
LCS did not show any growth inhibitory activity against the Bcc. DCS on the
other hand could inhibit growth of all strains of the Bcc reference panel and acted
bactericidal towards the Bcc. DCS displayed MICs between 2 and 128 µg/ml,
which are in the same range or lower than previously published for clinical iso-
lates of M. tuberculosis. These results indicate that, in vitro, Bcc are at least as
susceptible towards DCS as M. tuberculosis, and that DCS might be of clinical
use in the treatment of Bcc infections. Since this thesis focuses on the lipid A
biosynthesis and aminoarabinose modification pathways as drug targets, in vitro
CS inhibition with the only PLP-dependent enzyme, ArnB, involved in these
pathways was studied. Recombinant ArnB from B. cenocepacia J2315 was inhib-
ited reversibly by DCS. ArnB was further explored as a promising drug-target
in the Bcc, by using the other well known PLP dependent enzyme inhibitors β-
chloro-D-alanine and L-propargylglycine, but only CS could been identified as an
inhibitor so far.
The last topic covered in this thesis included lipid A transport and L-Ara4N
modification. I observed a striking similarity between the electron microscopic
images of the previously published B. cenocepacia ArnB and ArnT conditional
mutant strains [98] and the conditional lethal E. coli LptA/LptB mutant [165].
Therefore, it could be hypothesised that either LptA or LptB might show speci-
ficity to L-Ara4N-modified LPS. I explored and characterised two proteins which
are involved in lipid A transport: LptA, the periplasmic lipid A binding pro-
tein, and LptB, the cytoplasmic ATP-ase. LptA was found to be able to bind
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LPS in vitro. LptA could bind both modified and unmodified lipid A in vitro.
Furthermore, LptA could bind deep-rough-, rough-, and smooth- LPS, similar
to that described for Escherichia coli LptA. Therefore I concluded that LptA is
not L-Ara4N-specific. Recombinant B. cenocepacia LptB was expressed, purified
and the kinetic parameters were determined in vitro. The kinetic parameters were
found to be in a similar range as the values decribed for E. coli (kcat = 5.71 min
−1
and KM = 0.88 mM). The ATP-ase activity of LptB was not influenced by the
presence of any forms of LPS (modified or non-modified), suggesting the absence
of a regulatory protein domain that influences activity by LPS. Therefore, I con-





All chemicals and reagents were purchased from Sigma Aldrich, Fisher Scientific,
Biorad or Oxoid unless otherwise stated. DNA primers were purchased from
Sigma Aldrich. All restriction enzymes were purchased from New England Bi-
olabs. Competent cells were purchased from Promega, Invitrogen or Novagen.
All pET expression plasmids were purchased from Novagen. The (conditional)
knock out plasmids, pGpΩ plasmid and pSc200, and the Burkholderia cenocepa-
cia SAL-1 were given by Prof. M. A. Valvano (Department of Microbiology and
Immunology, University of Western Ontario, London, Ontario, Canada). E. coli
AY103 was given by Prof. C. H. R. Raetz (Department of Biochemistry, Duke
University Medical Center, Durham, North Carolina, USA). All chromatography
columns and affinity raisins were purchased from GE-Healthcare or Qiagen.
6.1.1 Cell lines, growth media, and antibiotics
All competent E. coli cell lines used in these studies are listed in Table 6.1.
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Table 6.1: Competent E. coli cell lines.
E.coli strain Relevant Characteristics
(source)
DH5α F− φ80dlacZ ∆M15 (∆lac2YA-argF)U169 endA1
(Novagen) recA1 hsdR17(rk
−mk
+) phoA supE44 thi-1 ∆gyrA96
relA1
JM109 endA1 recA1 gyrA96 thi hsdR17(rk
−mk
+) relA1
(Promega) supE44 ∆(lac-proAB), [F
′
traD36 proAB, laqIqZ∆M15]
TOP10 F− mcrA ∆(mrr -hsdRMS -mcrBC) φ80dlacZ ∆M15
(Invitrogen) ∆LacX74 deoR recA1 araD139 ∆ara-leu7697 galU galK
rpsL endA1 nupG
Bl21 (DE3) F− ompT hsdSb (rB
−mB
−) gal dcm (DE3)
(Novagen)




GT115 F− mcrA ∆(mrr -hsdRMS -mcrBC) φ80dlacZ ∆M15
(Invitrogen) ∆LacX74 recA1 endA1 ∆dcm, uiad (∆MluI )::pir -116,
∆sbcC-sbcD
Luria-Bertani (LB) broth contained 1% bacto-tryptone, 0.5% bacto-yeast ex-
tract, and 1% NaCl (pH7.5). LB agar was purchased from Invitrogen or Sigma.
Terrific Broth (TB) contained 1.2% bacto-tryptone, 2.4% bacto-yeast extract,
4 ml glycerol, and 17 mM KH2PO4/ 72 mM K2HPO4 (autoclaved separately).
2YT broth contained 1.6% bacto-tryptone, 1% bacto-yeast extract, and 0.5%
NaCl (pH7.5).
S-Gal agar was obtained from Sigma.
SOC contained 2% bacto-tryptone, 0.5% bacto-yeast extract, 0.05% NaCl, 0.5%
MgSO4, and 3.2% glucose (pH7.5).
Nutrient agar, Isosensitest (IS) broth, IS agar, Mueller Hinton (MH)
broth, and MH agar were purchased from Oxoid.
Antibiotics: When required cultures were supplemented with the following
antibiotics (final concentrations): ampicillin, 100 µg/ml; kanamycin 50 µg/ml;
gentamycin, 50 µg/ml; tetracycline, 50 µg/ml; and trimethoprim 50 µg/ml. All
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strains were grown at 37 oC unless stated otherwise.
6.2 General Methods
6.2.1 Introduction of plasmid DNA into bacterial cells
Transformation of competent E. coli cells
Competent cells were defrosted on ice, 3 µL of plasmid DNA was added, and
incubated on ice for 30 minutes. The cells were heat-shocked for 30 seconds at
44 oC, and allowed to close by incubation on ice for 2 minutes. 250 µL LB or
SOC medium was added, the cells were agitated (250 rpm) for an hour at 37 oC,
spread on LB agar containing the appropriate antibiotic, and incubated overnight
at 37 oC.
Tri-parental mating
E. coli DH5α or E. coli GT115 was transformed (as described above) with the
knock-out plasmid to become a donor strain. The helper strain was created by
transforming the pRK2013 plasmid into E. coli DH5α. The donor-, and helper-
strains were grown overnight in 10 ml SOB broth with appropriate antibiotic
selection. Recipient strains were grown overnight in 10 ml LB. All overnight
cultures were pelleted. The helper- and donor- strain were both resuspended
in 3 ml PBS, of which 1 ml of each was used to resuspend the recipient strain.
The mixture was washed 3 times with PBS and resuspended in 2 ml LB. 200 µL
was pipetted onto a 0.12 µM cellulose filter, which was placed onto a SOB agar
plate without any antibiotic selection. The plate was incubated upright overnight
at 37 oC. The filter was washed in 10 ml LB, of which 200 µL was spread on
a LB agar plate containing two different antibiotics. The first antibiotic used
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corresponded to the antibiotic resistance cassette of the knock-out plasmid. The
second antibiotic was an antibiotic where the recipient strain is naturally resistant
to but kills the donor and helper strain (in these studies on Burkholderia species,
gentamycin was used). After 2 days, surviving colonies were spread on fresh LB
plates containing the same antibiotics. The presence of the plasmid or insertion
of the construct into the genome was confirmed by PCR.
6.2.2 DNA & RNA
Isolation of genomic DNA
Chromosomal DNA was isolated using alkaline lysis extraction. Bacterial colonies
were scraped from a plate and mixed into 20 µL lysis buffer (2.5 ml 10% SDS,
5 ml 1 M NaOH, 92.5 ml dH2O), which was then heated to 95
oC for 15 minutes.
After a quick spin in a centrifuge, 180 µL dH2O was added. It was centrifuged
for 5 minutes at 13,000 rpm, and stored at -20 oC.
DNA gel electrophoresis
1.2% or 4% agarose was added to TAE buffer and heated in a microwave until
dissolved. The molten agarose was cooled to approximately 50 oC, ethidium
bromide was added to a final concentration of 5 µg/ml. The molten agarose was
poored into the casting and allowed to set at room temperature. DNA loading
dye (Novagen) was added to the DNA samples and the gel was ran in TAE buffer
at 100 V for 30-60 minutes.
DNA purification
For isolation of DNA restriction fragments or PCR products from 1.2% agarose
gels, the Qiagen Gel Extraction kit was used. Plasmids were isolated from E. coli
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cells using the Qiagen Miniprep kit. Both extractions were carried out according
to the protocol of the manufacturer.
Polymerase chain reaction (PCR)
All PCR reactions were carried out in a Techne TC-3000 hot-lid Thermal Cycler.
Proofstart polymerase (Qiagen) was used for the PCR reactions unless otherwise
stated. The total reaction volume was 50 µL, containing 10 µM forward and
reverse primer, 4 µL genomic DNA (isolated as described above), 5 µL buffer,
10 µL solution Q, 200 µM dNTPs, 1 µL polymerase, and dH2O. Typically, the
reaction was cycled 35 times, denaturing at 95 oC for 30 seconds, followed by
annealing (specific temperatures are given for every primer-set) for 30 seconds,
and elongation at 72 oC for 1 minute per 1000 bp. For cloning into pGEM-T-
Easy (Promega), which requires the addition of a poly(A) tail on both ends of the
PCR product, a puReTaq Ready-To-Go bead (GE Healthcare) was added after
the PCR reaction. The mixture was heated to 95 oC for 5 minutes, followed by
an elongation step of 10 minutes at 72 oC.
Restriction digests
For a small scale restriction digest (total volume of 10 µL), 1 µL 10 x appropriate
buffer was added to 8 µL of plasmid DNA, which was then mixed with 0.5 µL
of each endonuclease required. The mixture was incubated for at least 1 hour at
37 oC before analysis by DNA gel electrophoresis.
For a large scale restriction digest the total volume of the reaction was 50 µL
(43 µL plasmid DNA, 5 µL buffer, and 1 µL of each endonuclease). The procedure
was identical as described for the small scale restriction digest.
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Sequencing
The cloned plasmids were sequenced using a PCR-based method. The sequencing
reaction contained 5 µL plasmid (50-100 ng), 1 µL forward or reverse primer
(final concentration was 3.2 µM), 2 µL BigDye Terminator v3.1 5x sequencing
buffer (Applied Biosystems), and 2 µL BigDye. The reaction was cycled 30
times, 95 oC for 30 seconds, 45 oC for 15 seconds, and 60 oC for 4 minutes.
The primers used to sequence the pET expression- and pGEM-T-Easy plasmids
are listed in Table 6.2. Sequencing of the reaction product was carried out by
Genepool sequencing service, Institute for Cell and Molecular Biology, University
of Edinburgh. Sequencing data was analysed by Contig Express & Vector NTI
Advance TM V9 software package (Invitrogen).






pGEM T7 For (forward primer) TAATACGACTCACTATAGGG
pGEM T7 Rev (reverse primer) ATTTAGGTGACACTATAGAA
pET For (forward primer) TAATACGACTCACTATAGGG
pET Rev (reverse primer) ATTTAGGTGACACTATAGAA
Cloning
All PCR products were cloned into a pGEM-T-Easy vector, before further cloning
into an expression or knock-out plasmid. To do so, the purified DNA PCR prod-
uct was ligated into the pGEM-T-Easy plasmid, using either T4 DNA ligase
(Promega) or Quick time ligase (Roche) according to the instructions of the man-
ufacturer. The ligation product (3 µL) was transformed into E. coli JM109 com-
petent cells and spread on S-Gal/Amp plates, which allows for blue- (no insert)
white (insert)- colony screening. White colonies were picked, grown overnight
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in 5 ml LB/Amp, and the plasmid was isolated. The pGEM-T-Easy plasmids
were screened for the right insert by performing a small scale restriction digest.
Typically, restriction sites were incorporated in all forward- and reverse- primers.
Hence, the plasmid was restricted with the two corresponding endonucleases.
When possible, a second restriction digest was performed using an endonucle-
ase cleaving inside the gene of interest. The plasmids which showed the expected
digest profiles were sequenced. When sequencing confirmed the right insert (with-
out mutations), a large scale restriction digest was carried out of the pGEM-T-
Easy plasmid and the recipient plasmid. The digest products were separated by
DNA gel electrophoresis and purified. The insert and the recipient plasmid were
ligated and transformed into competent E. coli TOP10 or DH5α cells.
RecA & RFLP analysis
To confirm the identity of all Bcc strains used in this study, DNA was isolated
and the RecA gene was amplified using the primers BCR1 and BCR2 (Table 6.3).
The PCR consisted of 30 cycles: 30 seconds at 94 oC, 5 seconds at 58 oC, and
60 seconds at 72 oC; and a final extension of 10 minutes at 72 oC. 10 µL of PCR
product was ran on a 1.2% agarose gel (1 kb ladder) and 10 µL was restricted
overnight with HaeIII and ran on a 4% agarose gel (100 bp ladder).










Proteins were expressed in expressing E. coli cell lines (BL21(DE3) or HMS174(DE3)).
Small scale expression. To determine the expression conditions of the differ-
ent proteins, a small scale induction of the expression plasmid was performed. A
single colony of the expressing cell line was grown overnight in 5 ml LB broth. The
cells were diluted down 1/10 in 5 ml fresh broth and grown to an A600 of ∼0.6-
0.8. To trigger transcription of the lac operon, different concentrations (0.1 mM,
0.5 mM, 1.0 mM) of isopropyl β-D-1-thiogalactopyranoside (IPTG) were added.
The cells were grown for an additional 5 hours (unless stated otherwise) at 37 oC
and 500 µL samples were taken after 1 hour, 3 hours, and 5 hours. The samples
were spun down, and protein expression was analysed by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE).
Large scale expression. A single colony of the expressing cell line was grown
overnight in 250 ml LB medium containing the appropriate antibiotic. The
overnight cultures were diluted into 4 L fresh medium to an A600 of ∼0.1 and
grown to an A600 of ∼0.6-0.8 at 37 oC. Protein expression was induced by adding
IPTG to the cell culture, and the cells were grown for an additional amount of
hours, at the optimised temperature needed for protein expression. The cells were
harvested by centrifugation at 4,000 rpm and the pellets were stored at -20 oC.
SDS-PAGE
SDS-PAGE mini gels (15% acrylamide) were used to analyse proteins based on
their molecular weight. SDS-PAGE gels, loading buffer, staining solution and
destaining solution were prepared according to the Laemmeli protocol. Samples
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for analysis by SDS-PAGE were prepared by addition of appropriate volume of
loading buffer, followed by boiling the sample for 5 minutes, and centrifugation
(13,000 rpm, 5 min). The low molecular weight (LMW) marker (GE Healthcare)
or SeeBlue-Plus2-prestained standard (Invitrogen) was used as a reference for
size. Gels were typically run for 60 minutes, 200 V and 180 mA.
Western Blot
Western Blot analysis was performed to positively identify expressed and/ or
purified His6 tagged proteins. After running a SDS-PAGE mini gel the gel and
the nitrocellulose membrane (Hybond-ECL, Amersham) were placed into trans-
fer buffer (150 mM TRIS, 150 mM glycine, and 10% MeOH) for 10 minutes. Six
slightly larger Whatman filter papers were soaked into transfer buffer. The filter
papers, nitrocellulose membrane, and SDS-PAGE gel were placed on top of each
other (from bottom to top: 3 times filter paper, nitrocellulose membrane, gel, and
3 times filter paper) in the blotting machine (Trans-Blot SD Semi-Dry Transfer
Cell (Bio-Rad)) and blotted for 40 minutes, 15 V, and 150 mA. The membranes
were incubated overnight in blocking solution (0.1% Tween20 and 5% milk pow-
der dissolved PBS), with agitation at 4 oC. The membranes were washed 6 times
for 5 minutes with washing solution (0.1% Tween20 in PBS). Membranes were in-
cubated with blocking solution, containing 1:3000 µL Anti-His antibody (Roche)
for an hour, after which they were washed 6 times with washing solution and
incubated with blocking solution, containing 1:3000 Anti-Mouse antibody. The
membranes were washed 6 times with washing solution, were dried and covered
with ECL Plus Western Blotting Detection System solution (GE Healthcare).
The membrane was dried and the western blot was developed using KODAK
BioMax XAR film in a Hypercassette (Amersham).
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Cell lysis by sonication
The cell pellet was defrosted on ice and resuspended in lysis buffer (composition
is specified per protein) till a homogeneous suspension was obtained. The sus-
pension was sonicated on ice for 15 cycles (30 seconds on, 30 seconds off) using a
soniprep 150. The cell debris and supernatant were separated by centrifugation
(15,000 rpm, 20 minutes, 4 oC).
MALDI-TOF analysis of proteins
Proteins, in concentrations of typically 1 mg/ml, were co-crystallised with sinap-
inic acid (10 mg synapinic acid in 500 µL H2O, 400 µL acetonitrile and 100 µL 3%
trifluoroacetic acid (TFA)) as a matrix, directly on MALDI plate. Spectra were
measured on a Voyager DE-STR MALDI-TOF mass spectrometer and analysed
using the DataExplorer software (Applied Biosystems).
6.2.4 LPS
LPS extraction using hot-phenol
A single colony of the desired strain was picked and grown in 5 ml LB broth at
37 oC overnight. This 5 ml of culture was used to inoculate 4 L LB broth and
was grown overnight at 37oC. The cells were harvested by centrifugation (9,000g
for 20 minutes). When LPS of Burkholderia strains was isolated, the pellet was
boiled for 10 minutes to kill the cells (for transport purposes). For other strains
this step was omitted. The cell pellets were stored at -20 oC.
The pellet was resupended in 50 ml cold EDTA solution (0.05 M Na2HPO4*7H2O,
50 mM EDTA, pH 7). The cells were sonicated on ice for 15 minutes, 30 seconds
on, 30 seconds off. The mixture was transferred to a conical flask, 15 mg lysozyme
was added, and stirred overnight at 4 oC. The mixture was transferred to a 37 oC
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shaker and heated for 20 minutes. 20 mg RNAse, 0.4 mg DNAse, and 25 ml of
0.04 M MgCl2*6H2O was added and incubated for half an hour at 37
oC. The
mixture was then heated up to 60 oC in a waterbath. After reaching 60 oC,
both the mixture and a bottle with 75 ml phenol were heated to 65 oC in the
waterbath. The mixture was added to the hot phenol, stirred manually for 15
minutes at 65 oC, and incubated on ice for 15 minutes. To separate the water and
phenol phases, the mixture was centrifuged (9,000 g, 20 minutes, at 4 oC). After
separation, the phenol phase was transferred to dialysis tubing. The filled dialysis
tubing was placed in bucket filled with ∼7 L water and dialysed with a constant
flow of fresh water for 3 days. The samples were transferred to new falcon tubes
and kept at -80 oC overnight. The samples were lyophilised and stored at -20 oC.
By running a SDS-PAGE gel the presence of LPS was confirmed. Before using
it for my experiments the LPS was cleaned up. The LPS was resuspended in
LPS-free dH2O, ultra-centrifuged at 100,000 g, and lyophilised.
LPS extraction using Tri-reagent
A single colony of the desired strain was picked and grown in 1 L 2YT broth
overnight. The cells were harvested by centrifugation (9,000 g for 20 minutes).
The cell-pellet was lyophilised. The dried cells were resuspended into 10 ml Tri-
reagent and incubated for 20 minutes at room temperature. Chloroform (3 ml)
was added and incubated for 10 minutes at room temperature. To separate the
aqueous phase and the organic phase, the samples were centrifuged for 15 minutes
at 12,000 g. The aqueous phase (upper) was transferred to a new tube and
the organic phase was re-extracted 3 times by adding 10 ml dH2O, incubate 10
minutes at room temperature and centrifuge for 15 minutes at 12,000 g. The
aqueous phases of all extractions were combined and lyophilized. Then, 25 ml of
375 mM MgCl in 95% EtOH was used to re-dissolve the dried material, cooled
down to 0 oC (in -20oC freezer), and spun down at 12,000 g for 15 minutes. The
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supernatant was discarded and the pellet (conaining the LPS) was resuspended
in 7 ml of dH2O and lyophilized. By running a SDS-PAGE gel the presence of
LPS was confirmed and used for further experiments.
6.3 CHIR-090 & LpxC methods
6.3.1 Bacterial strains and growth conditions
To determine the sensitivity of members of the Bcc to CHIR-090, using the disc
diffusion assay, a panel of relevant strains was assembled against which CHIR-
090 was tested (Tabl 2.1). This panel included the Bcc experimental strain
panel [35, 38], together with B. cenocepacia SAL1 [183], P. aeruginosa PAO1,
and E. coli K12 MG1655.
For MIC determination of CHIR-090 against B. multivorans, the selected panel
of species consisted of the eight B. multivorans strains of the experimental strain
panel [38, 35]. As positive control strains E. coli ATCC25922, P. aeruginosa
ATCC27853, and P. aeruginosa ATCC10145 were used as suggested by the BSAC
guidelines [184].
All strains were typically grown on nutrient agar, unless otherwise stated. Before
doing disc diffusion tests and MIC determinations, the strains were recovered
from storage (-80 oC freezer) by growing them 3 times on fresh nutrient plates
and allow them to grow at 37 oC overnight. Prior to experiments, the identity of
the Bcc strains was confirmed by RecA/ RFLP analysis (described above).
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6.3.2 Antibiotic susceptibility testing of CHIR-090
Antibacterial disk diffusion tests
Single colonies of each organism were picked and grown overnight in 5 ml IS broth
and sub-cultured (1/10) the next day in fresh IS broth. The strains were grown
for an additional 2 hours at 37 oC to mid-log phase and then diluted with saline
(0.85% NaCl) to an A600 of 0.1. This culture was spread on IS agar plates to
provide a lawn of confluent growth. The remaining liquid was suctioned of the
plates and the plates were allowed to dry for 1 hour at room temperature. Then,
the discs, containing CHIR-090, were placed on top of the agar.
CHIR-090 was dissolved in dimethyl sulfoxide (DMSO), and six stock solutions
were prepared (0-, 0.25-, 1.25-, 2.5-, 5-, and 10 mg/ml CHIR-090). Six sterile
Whatmann filter paper disks were dotted with 0-, 1-, 5-, 10-, 20-, or 40 µg CHIR-
090 by adding 4µL of the correct stock solution. After dotting, the filter disks
were directly placed on top of the agar plates. The plates were incubated for 18
hours at 37 oC and the diameters of the inhibition zones were measured.
MIC determination
MIC data was generated for all B. multivorans strains of the Bcc reference panel as
described in the BSAC guidelines [184]. Single colonies of the strains were picked
and grown overnight in 10 ml nutrient broth + 0.5% yeast extract. The next day,
cultures were diluted 1/10 in fresh broth and grown for an additional 2 hours at
37 oC to mid-log phase. All strains were diluted 1/10 in saline (0.85% NaCl).
Those dilutions were used in conjunction with a multipoint inoculator (Denley) to
spot ∼104 colony forming units (cfu) onto the CHIR-090 containing ISTA plates.
Due to the limited amount of CHIR-090 available, plates were poured with 10 ml
ISTA, instead of the standard 20 ml volume. The plates containing different
concentrations of CHIR-090 ranging from 0 to 100 µg/ml (0-, 0.006-, 0.0125-,
124
0.025-, 0.05-, 0.1-, 0.2-, 0.4-, 0.8-, 1.6-, 3.2-, 6.4-, 12.5-, 25-, 50-, 100 µg/ml),
were inoculated, allowed to dry, and incubated at 37 oC for 18 hours. MICs were
calculated as the lowest concentration of antibiotic where no growth could be
observed.
6.3.3 LpxC2: genome analysis and genetic modification
LpxC2 presence check in the Bcc genomes
All Bcc strains within the Bcc reference panel were checked for the presence of
the LpxC2 gene in the genome. DNA was isolated of all Bcc strains using the
alkaline lysis extraction method described in section 5.2.2. A DNA sequence align-
ment was made with all the LpxC2 gene sequences available in the Burkholderia
database (www.burkholderia.com) at the time these studies were performed, also
including LpxC2 genes of Burkholderia species that do not belong to the Bcc.
PCR primers were designed on high homology regions of the genes (Table 6.4),
amplifying a 321 bp fragment. Furthermore, it was confirmed that the primer
sequences were specific (low sequence homology to other regions in the genome).







Samples were prepared as follows: 1 puReTaq Ready-To-Go beads (GE Health-
care), 1 µl forward primer, 1 µl reverse primer, 3 µl total genomic DNA, and
20 µl H2O. The reactions were initiated with a hot-start of 5 minutes at 95
oC
and cycled 40 times at 95 oC for 30 seconds, 55 oC for 30 seconds, and 72 oC for
30 seconds.
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Inactivation of Bcc genes using (conditional) knock-out plasmids
Insertional inactivation of LpxC1 and LpxC2 in B. cenocepacia K56-2 was at-
tempted using the suicide pGpΩTp plasmid, as described previously [190]. A
∼300 bp fragment inside of the target genes was amplified and cloned into the
pGpΩTp plasmid. E. coli GT115 cells were transformed with the plasmid. The
construct was introduced into B. cenocepacia K56-2 by tri-parental mating, using
E. coli GT115 as the donor strain. Surviving colonies were verified by PCR using
a forward primer at the beginning of the gene and the RSF1300 primer, which
is specific for the plasmid. To note is that with this procedure no colonies were
obtained with the correct insertion.
Conditional inactivation of LpxC2 in B. cenocepacia K56-2 was attempted using
the pSC200 plasmid, as described previously [98]. The first 300 bp of LpxC2, start-
ing at ATG, were cloned into the pSc200 plasmid (using the NdeI and XbaI restric-
tion sites). E. coli GT115 cells were transformed with the plasmid. Transformed
cells were streaked onto LB agar plates containing 0.2% glucose and trimethoprim.
The construct was introduced into B. cenocepacia K56-2 by tri-parental mating,
using E. coli GT115 as the donor strain, and LB plates containing 0.2% rham-
nose. Surviving colonies were verified by PCR using a forward primer upstream
of the site of insertion and the RSF1300 primer, which is specific for the plasmid.
The conditional LpxC2 mutant B. cenocepacia strain created was grown on LB
containing 0.2% rhamnose, until the mutant was further explored. Then the
mutant strain was streaked 3 times on LB agar containing 0.2% glucose (no
rhamnose) to test for survival. Then, a disc diffusion assay was carried out with
40 µg CHIR-090 (as described above) using LB agar containing 0.2% glucose (no
rhamnose).
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6.3.4 LpxC1 & LpxC2: cloning and expression
DNA was isolated from B. cenocepacia J2315 using the alkaline lysis method de-
scibed previously. The LpxC1 gene (BCAL3455) was amplified with the primers
listed in Table 6.5, using PCR (annealing temperature was 55 oC). The cloning
procedure as described in section 3.2.2 was followed. The LpxC1 gene was cloned
into the expression plasmid pET22b (using the NdeI and EcoRI restriction sites),
giving pET22b LpxC1 J2315 (Figure 6.1). The construct contains an IPTG in-
ducible promotor for controlled expression, and expresses LpxC1 without a fusion
tag.







Figure 6.1: Plasmid map of pET22b LpxC1 J2315.
A synthetic gene (cloned into pUC57) encoding LpxC2 was ordered from Gen-
Script. The synthetic gene was cloned into the expression vector pET22b (using
the NdeI and XhoI restriction sites), giving pET22b LpxC2 J2315 (Figure 6.2).
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The plasmid contains an IPTG inducible promotor, and as for pET22b LpxC1 J2315,
should express LpxC2 without a fusion tag.
Figure 6.2: Plasmid map of pET22b LpxC2 J2315.
A small scale expression was carried out to confirm expression of the plasmids
pET22b LpxC1 J2315 and pET22b LpxC2 J2315, as described in section 3.2.3.
Protein expression was induced in E. coli HMS174 (DE3) and BL21 (DE3) cells.
Different temperatures (e.g. 37 oC, 30 oC, and 18 oC) and times (e.g. 3-,5-
,18 hours) of expression were tested.
6.4 Cycloserine & ArnB methods
6.4.1 Antibiotic susceptibility and synergy testing of cy-
closerine
MIC determination
MIC data was generated for all Bcc strains within the Bcc reference panel [35, 38]
as described in the BSAC guidelines [184]. The same procedure was followed as
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described in section 5.3.2 for CHIR-090. The plates contained different concen-
trations of LCS (Sigma Aldrich) or DCS (Duchefa Biochemie) ranging from 0 to
128 µg/ml (0-, 0.06-, 0.125-, 0.25-, 0.5-, 1-, 2-, 4-, 8-, 16-, 32-, 64-, 128 µg/ml)
for LCS and from 0 to 1000 µg/ml (0-, 0.06-, 0.125-, 0.25-, 0.5-, 1-, 2-, 4-, 8-,
16-, 32-, 64-, 128-, 250-, 500-, 1000 µg/ml), were inoculated, allowed to dry, and
incubated at 37 oC for 18 hours.
MBC determination
MBCs were determined for a selection of strains, including: three B. multivorans
strains (C5393, C1575 and ATCC17616), three B. cenocepacia strains (J2315,
K56-2 and ATCC17765) and the two control strains E. coli ATCC25922 and
P. aeruginosa ATCC10145. Single colonies of the strains were picked and grown
overnight in 10 ml nutrient broth + 0.5% yeast extract. The next day, cultures
were diluted 1/10 in fresh broth and grown for an additional 2 hours at 37 oC to
mid-log phase. Serial dilutions of DCS were made (ranging from 0 to 500 µg/ml
final concentration; 0-, 2-, 4-, 8-, 16-, 32-, 64-, 128-, 250-, 500 µg/ml) in 0.9 ml of
IS broth in WR tubes. The mid-log phase cultures were diluted 1/100 cells/ml
and 100 µL was added to each dilution of antibiotic. The broths were incubated
overnight at 37 oC without agitation. The next day, 50 µL of the first (MIC
concentration) and second serial dilution where no growth could be observed
was plated onto a nutrient agar plate (without antibiotics) and grown at 37 oC
overnight. When no growth could be observed the following day DCS was called
bactericidal and when a confluent lane of growth could be observed DCS was
called bacteriostatic. MBCs were determined as the lowest concentration of DCS
were no growth could be recovered.
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6.4.2 DCS synergy studies
For synergy studies a selection of Bcc strains was used; three B. multivorans
strains LMG13010, C1576 and ATCC17616; three B. cenocepacia strains K56-2,
Sal-1 and J2315; B. dolosa AU0645; two control strains P. aeruginosa ATCC10145
and E. coli ATCC25922. Synergy studies of DCS (100 µg) were performed with
chloramphenicol (30 µg), trimethoprim (5 µg), tobramycin (10 µg), meropenem
(10 µg), minocycline (30 µg), ceftazidime (30 µg) and ciprofloxacin (5 µg). A
disc diffusion test (as described for CHIR-090) was done with single antibiotic
discs on IS agar. The radius of the killing zones was measured of the individual
antibiotics. When no zone of inhibition was observed for one of the strains, the
strain was excluded for that particular antibiotic in the next step. Then, a double
disc diffusion test was carried out. One filter disc was impregnated with DCS and
the other with one of the above-mentioned antibiotics. The two discs were placed
together on the agar plates at a distance that equaled the sum of the radii of the
two individual antibiotics. The plates were incubated for 18 hours at 37 oC and
the zones of inhibition were examined.
6.4.3 Expression and purification of ArnB-His6
The plasmid pET22b ArnB J2315 (Figure 6.3) was created by Thomas Varques
(PhD student Campopiano lab). It contains an IPTG inducible promotor for con-
trolled expression, and expresses ArnB with a C-terminal His6 fusion tag. To ex-
press ArnB-His6, E. coli BL21 (DE3) was transformed with pET22b ArnB J2315
and a large scale grow (see section 1.2.3) was carried out. Expression of ArnB
was induced for 5 hours by adding 0.5 mM IPTG. The cell pellet was resus-
pended in Buffer A (20 mM Kphos, 150 mM NaCl and 25 µM PLP) containing
100 µg/ml lysozyme and a protease inhibitor tablet (Roche diagnostic, GmbH
complete EDTA free). The cells were disrupted by sonication and unbroken cells
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Figure 6.3: Plasmid map of pET22b ArnB J2315.
and cell debris were removed by centrifugation at 12,000 g for 30 minutes. The sol-
uble lysate was applied to a 1 ml polypropylene column loaded with 1 ml Ni-NTA
Superflow resin (Qiagen) that had been pre-equilibrated with Buffer A contain-
ing 20 mM imidazole. After loading the column it was washed with 100 column
volumes (cv) of Buffer A containing 20 mM imidazole. ArnB-His6 was eluted off
in 20 cv Buffer A containing 200 mM imidazole. The eluate was concentrated to
a volume of ∼1 ml using a 30.000 Da MWCO vivaspin column (Sartorius Stedim
Biotech). ArnB-His6 was further purified by size exclusion chromatography using
a calibrated HiPrep 26/60 Sephacryl S-200 column (GE Healthcare). The column
was equilibrated with 1 cv Buffer A, the protein was loaded onto the column, and
1 cv of Buffer A was run through at 1 ml/min. 10 ml fractions were collected and
analysed by SDS-PAGE. Fractions containing pure ArnB were pooled and stored
at -80 oC in Buffer A containing 20% glycerol.
The molecular mass of ArnB-His6 estimated from the S-200 column elution vol-
ume and the molecular mass was confirmed by MALDI-TOF analysis.
131
6.4.4 ArnB-His6 activity and inhibition assay
Prior to the assays, ArnB-His6 was defrosted and dialysed overnight in Buffer A
containing an excess of PLP (e.g 100 µM). Dialysis buffer was refreshed three
times. To remove the unbound PLP, the dialysed sample was concentrated to
a volume of 1.5 ml and loaded on a PD-10 column (GE-Healthcare), that was
pre-equilibrated with Buffer A. ArnB-His6 was eluted of the column with 5 ml
Buffer A. The protein concentration was determined by taking the absorbency in
an Cary 50 UV visible photospectrometer (Varian) at 280 nm. All assays were
carried out in a final volume of 500 µL Buffer A containing 14 µM ArnB-His6, in
a UV visible photospectrometer at 25 oC measuring between a wavelength of 200
and 800 nm, using a quartz cuvette. Spectra were analysed using Cary WinUV
software (Varian), and graphs were generated using Sigma Plot software.
The reversibility of the (inhibition) reactions was tested by dialysis. 2 ml of com-
pleted reaction mixture (E-PLP) was dialysed overnight against 250 ml Buffer A
containing 100 µM fresh PLP. Than the protein was loaded on a PD-10 column to
remove unbound PLP. The protein was eluted in 5 ml Buffer A and concentrated
to the required protein concentration for the assays. Then, a new reaction with
L-glutamate was carried out as described below.
ArnB-His6 and L-glutamate
A scan was taken of the holo-enzyme (E-PMP) before the start of the assay.
Reactions were initiated by the addition of 500 µM L-glutamate. Scans were
taken every six seconds till no change in absorbance spectra was observed.
ArnB-His6 inhibition by CS
A scan was taken before the reaction (showing the holo-enzyme). Reactions were
initiated with 1 mM DCS or 1 mM LCS. Scans were taken every minute till the
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reaction completed. After completion of the reaction, two additional experiment
were performed: 1) When there was no change in spectra observed anymore,
500 µM L-glutamate was added to the completed reaction mixture to check for
any change in spectra (activity); 2) The reversibility of DCS and LCS inhibition
was tested as described above.
ArnB-His6 inhibition by βCDA
A scan was taken before the initiation of the reaction. The reactions were initiated
by the addition of 500 µM, 1 mM, or 2 mM βCDA. Scans were taken every minute
till no change in spectra could be observed. To test if βCDA was inhibiting the
enzyme or was used as a substrate by the enzyme, we scanned for the release of
pyruvate in the reaction mixture. After completion of the reaction, a scan was
taken at 340 nm, 150 µM NADH was added to the reaction mixture and the
expected increase of absorbance was confirmed at 340 nm. Then, 0.4 U/ml LDH
was added to the reaction mixture and the decrease in absorbance at 340 nm
was measured over time. As controls for this experiment, NADH and LDH were
added in the same concentrations to Buffer A containing 2 mM βCDA or buffer A
containing 14 µM ArnB-His6 and the absorbance at 340 nM was measured over
time.
ArnB-His6 inhibition by L-PPG
A scan was taken before the initiation of the reaction. The reactions were initiated
by the addition of 500 µM L-PPG. Scans were taken after 10 minutes, 1 hour,
5 hours, and 24 hours. When there was no change in spectra observed anymore,
500 µM L-glutamate was added to the completed reaction mixture to check for any
change in spectra (activity), and the reversibility was tested by dialysis against
fresh PLP, as described above.
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6.5 LptA &LptB methods
6.5.1 Cloning, expressing and purification of LptA
Plasmid pET22b LptA J2315 (Figure 6.4) expresses LptA of B. cenocepacia J2315
with a C-terminal His6 tag upon IPTG induction. pET22b LptA J2315 was con-
structed by PCR amplifying the LptA open reading frame (BCAL0815) from
genomic DNA with primers LptAFW1 and LptAREV 1 (Table 6.6). LptA was
cloned into pET22b using the NdeI-XhoI restriction sites. A large scale ex-







Figure 6.4: Plasmid map of pET22b LptA J2315.
pression was carried out using E. coli HMS174 (DE3) cells carrying the plasmid
pET22b LptA J2315 in TB, containing 5 times the recommended amount of glyc-
erol. The cells were induced for 1-1.5 hours with 0.1 mM IPTG at 37 oC. The
cells were harvested by centrifugation and stored at -20 oC until purification.
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All the following steps were performed at 0-4 oC. The pellet was resuspended into
Buffer B (20 mM Na2HPO4 (pH 7.5), 300 mM NaCl) containing a protease in-
hibitor tablet (Roche) and 20 mM imidazole, and the cells were disrupted by son-
ication. Unbroken cells and cellular debris was removed by centrifugation. LptA-
His6 was purified with nickel affinity chromatography by adding 1 ml Ni-NTA
raisin to the supernatant and was gently mixed for 1 hour. The protein bound
Ni:NTA beads were loaded into a 1 ml polypropylene column using a periplastic
pump. The raisin was washed with 30 cv Buffe B containing 20 mM imidazole
and the protein was eluted in 15 cv 250 mM imidazole containing Buffer B. The
elution fraction was dialysed against Buffer C (25 mM HEPES (pH 7.5, 150 mM
NaCl) and LptA-His6 was further purified by size exclusion chromatography us-
ing a calibrated HR 26/60 Sephacryl S-300 column (GE Healthcare). The column
was equilibrated with 1 cv Buffer C, the protein was loaded onto the column, and
1 cv of Buffer C was run through at 1 ml/min. 10 ml fractions were collected
and analysed by SDS-PAGE. Fractions containing LptA-His6 were pooled and
used for further studies. The oligomerisation status of LptA-His6 was estimated
from the S-300 column elution volume and the molecular mass was confirmed by
MALDI-TOF analysis.
6.5.2 LptA: LPS binding assays
The LPS used in this study was prepared in the following way: Smooth LPS of
E. coli AY103 was isolated using the tri-reagent method, as described in section
5.2.4. Rough LPS of B. cenocepacia J2315 was isolated using the the hot water-
phenol mehod. Deep-rough LPS of B. cenocepacia Sal-1was isolated using either
the tri-reagent or hot water-phenol mehod. E. coli Kdo2-lipid A was purchased
from Avanti Polar Lipids.
The in vitro LPS binding assay was carried out in a similar fashion as described
previously [171] with some modifications. Purified LPS (300 µg) or purchased
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Kdo2-lipid A (100 µg) was added to 500 µl Buffer C containing 0.5 mg/ml LptA-
His6. The mixture was incubated at room temperature for 1 hour with agitation.
Then, Ni-NTA raisin was added to the sample and was gently mixed for 10
minutes. The protein bound Ni:NTA beads were washed 5 times with 1 mL
Buffer C to remove unbound LPS. Then, the protein and Ni:NTA beads were
separated by adding 500 µl Buffer C containing 300 mM imidazole. The samples
were analysed by SDS-PAGE followed by silverstaining (according to the protocol
of the manufacturer, Sigma).
6.5.3 Cloning, expressing and purification of LptB
Plasmid pET22b LptB J2315 (Figure 6.5) expresses LptB of B. cenocepacia J2315
with a C-terminal His6 tag upon IPTG induction. pET22b LptB J2315 was con-
structed by PCR amplifying, using QIAGEN proofstart polymerase and TAQ
bead extension, the LptB open reading frame (BCAL0814) from genomic DNA
with primers LptBFW1 and LptBREV 1 (Table 6.7). The PCR product was cloned
into the recombinant protein expression plasmid pET22b, using the NdeI-HindIII
restriction sites. E. coli BL21 carrying the plasmid pET22b LptB J2315 was







grown at 37 oC in LB broth to an A600 of 0.6-0.8. The cells were induced with
0.1 mM IPTG and grown for an additional 18 hours at 18 oC. The cells were
harvested by centrifugation and stored at -20 oC until purification. The purifi-
cation condition of the E. coli LptB-His6 protein were published recently [169],
and the same strategy was adapted with some modifications. The LptB-His6 ex-
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Figure 6.5: Plasmid map of pET22b LptB J2315.
pressing cells were resuspended in LptB lysis buffer (∼4 ml/ gram of cell paste).
LptB buffer contained 50 mM HEPES buffer (pH 7.5), 10% glycerol, 150 mM
potassium chloride (KCl), 1mM dithiothreitol (DTT), 5 mM magnesium chloride
(MgCl). For LptB lysis buffer, 1 mM phenylmethylsulphonyl (PMSF), 100 µg/ml
lysozyme and 2 Units/ml DNAseI (Roche) was added.
The cells were incubated on ice for 30 minutes, followed by sonication. Cell debris
was removed by centrifugation and the cell free extract was pressed through a
0.45 µM filter. A 1 ml polypropylene column was loaded with ml Ni-NTA Su-
perflow resin (Qiagen). The column was pre-washed with 10 cv LptB buffer, and
equilibrated with 10 cv LptB buffer plus 20 mM imidazole. The cell free extract
was passed through the column at 0.75 ml/min using a periplastic pump. The
column was washed at 1.5 ml/min with 100 cv of LptB buffer containing 20 mM
imidazole and the protein was eluted at 0.75 ml/min with 15 cv LptB buffer plus
300 mM imidazole. The eluate was dialysed against LptB buffer for 2 hours to
remove the imidazole, and concentrated to a volume of ∼1 ml using a 10,000 Da
MWCO vivaspin column (Sartorius Stedim Biotech).
The protein was further purified using the calibrated Superdex 75, 16-60 HR, a
size exclusion chromatography column (GE Healthcare). The column was equili-
brated with 1 cv (120 ml) LptB buffer. The protein was loaded onto the column
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after which 1 cv at a flow rate 1 ml/min of LptB buffer ran through the column
to elute the protein. Fractions of 5 ml were collected and analysed by SDS-PAGE.
6.5.4 LptB-His6 activity, kinetic analysis and inhibition
LptB-His6 activity assay
The LptB-His6 enzyme was assayed using a coupled, three enzyme system, with
LptB-His6, pyruvate kinase, and lactate dehydrogenase. The conditions described
for E. coli LptB [169] were adapted with slight modifications. The LptB-His6
reaction mixture consisted off (final concentrations): 100 mM HEPES, 10% glyc-
erol, 150 mM KCl, 5 mM MgCl, 1 mM DTT, 10 µM LptB (based on absorbance
at 280 nm), 3.31 U/ml pyruvate kinase (PK), 4.03 U/ml lactate dehydrogenase
(LDH), 0.25 mg/ml BSA, 4 mM phospo(enol) pyruvic acid (PEP) and 0.3 mM
NADH. The assays were carried out in a UV visible photospectrometer (Varian)
at 25 oC measuring at a wavelength of 340 nm. For the assay 400 µL of reaction
mixture was used per reaction, using 500 µL quartz cuvettes. Reactions were
initiated by the addition of ATP (50 µL) in the reaction cuvette. The decrease
in NADH absorbance at 340 nm was measured over time, which is proportional
to the amount of ATP hydrolyzed. All assays were carried out in triplo, and as
a control the mixture was measured without the addition of ATP.
Kinetic analysis of LptB-6His
Using the LptB-His6 activity assay conditions as described above, the LptB-His6
kinetics were determined by altering the final ATP concentrations (8 mM, 4 mM,
3 mM, 2 mM, 1.5 mM, 1 mM, 750 µM, 500 µM, 375 µM, 250 µM, 125 µM,
62.5 µM, 31.25 µM, and 0 (blank)). The initial rate of reaction (-slope) was
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calculated from a linear portion of the plot, using kinetics software (Varian).
The extinction coefficient of NADH at 340 nm is ε = 6220 M−1 cm−1 in a 1 cm
path quartz cuvette. Sigma-plot software was used to fit the data by non-linear
regression.
The Hill-coefficient, which is useful to characterise the cooperative behavior of





Were n= Hill constant, K= the dissociation constant, [S]= the free (unbound)
substrate concentration, and Ys= fraction of occupied sites where the substrate
can bind. The quantity of n increases with the degree of cooperativity. When
n= 1, the substrate-binding reaction is non-cooperative. If n= <1, the substrate-
binding reaction is negative-cooperative. And in case n= >1 the, he substrate-
binding reaction is positively-cooperative, indicating that the enzyme acts as
a dimer. The Hill coefficient can also be graphically determined (Sigma Plot






= n log[S]− logK (6.2)
LptB-His6 inhibition studies
Inhibition studies of LptB-6His were performed under the conditions as described
above. The final ATP concentrations used to measure inhibition were 2 mM,
1 mM and 0.5 mM respectively.
Sodium orthovanadate: The final concentrations of sodium orthovanadate
(Sigma) in the reaction mixture were adapted from published data on E. coli
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LptB [168]. Concentrations tested were 8 mM, 4 mM, 2 mM, 1 mM, 0.5 mM,
0.25 mM, and 0.12 mM, with pre-incubation times of inhibitor and enzyme (re-
action mixture without ATP) ranging from 0 to 60 minutes at 25 oC. The initial
rate of reaction was compared with and without inhibitor.
Inhibitor 2: Inhibitor 2 (5-[1-[5-(4-Fluoro-2-hydroxy-phenyl)-furan-2-yl]-meth-
(Z)-ylidene]-thiazolidine-2,4-dione) was purchased from Axon MedChem. The
final concentrations of inhibitor tested in the reaction mixture was adapted from
published data on E. coli LptB-His6 [169]. Concentrations tested were 22 µM,
18 µM, 12 µM, 6 µM, 3 µM, and 1 µM, with pre-incubation times of inhibitor
and enzyme (reaction mixture without ATP) ranging from 0 to 120 minutes at
25 oC. The initial rate of reaction was compared with and without inhibitor.
LptB-6His activity stimulation by its ”substrate”
The ATP-ase activity of LptB-6His was measured in the presence and absence
of purchased Kdo2-lipid A, isolated LPS from the two B. cenocepacia strains,
J2315 and SAL-1, and the two mutated E. coli strains AY103 (ArnT knock out)
and MST100 (pmrA overexpressing) [152]. Concentrations tested were 20 µg/ml,
2 µg/ml, 200 ng/ml, 20 ng/ml, and 2 ng/ml. The initial rate of reaction was
compared within and without the presence of LPS.
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Figure A.2: LpxC alignment of E. coli, P. aeruginosa, A. aeolicus, and B. ceno-
cepacia J2315 (LpxC1 and LpxC2). The amino acids important for CHIR-090
binding are indicated.
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Figure A.3: Alignment of B. cenocepacia J2315 ArnB and S. typhimurium ArnB.
The amino acids involved in stabilisation of the PMP-cycloserine adduct (orange),
(amino donor) substrate binding (blue), and the lysine residue (purple, K188)
forming a bond with PLP, are indicated.
Figure A.4: ArnB-His6 MALDI-TOF mass spectometry analysis.
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Figure A.5: E-PMP ArnB-His6 post-dialysis (=E-PLP) against an access of PLP
overnight (solid line) and ArnB-His6 (post dialysis) reacted with 500 µM L-
glutamate for 1 minute (dashed line)
Figure A.6: Absorbance spectra for ArnB-His6 in the E-PLP form (black), 10
minutes after addition of 1 mM DCS (blue-dashed), 3 hours after the addition of
1 mM DCS (blue-solid), DCS-ArnB-His6 post-dialysis against an access of PLP
overnight (red-solid) and DCS-ArnB-His6 (post-dialysis) reacted with 500 µM
L-glutamate for 1 minute (red-dashed)
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Figure A.7: Absorbance spectra for ArnB-His6 in the E-PLP form (grey). LCS-
ArnB-His6 post-dialysis against an access of PLP overnight (green), LCS-ArnB-
His6 (post dialysis) reacted with 500 µM L-glutamate for 1 minute (blue), and
base-line (red).
Figure A.8: Recombinant LptA B. cenocepacia sequence. The signal peptide
(blue) and the C-terminal His6 tag (red) are indicated.
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Figure A.9: LptA-His6 MALDI-TOF mass spectometry analysis, 0 hours (A)-






































































































Figure A.11: Alignment of B. cenocepacia J2315 LptB and E. coli LptB. The
amino acids forming the Walker A motif (ATP-binding site) and the ”ABC trans-
porters family signature” are indicated.
Figure A.12: LptB-His6 MALDI-TOF mass spectometry analysis.
161
Appendix A
Publications
162
